CLINICAL REVIEW

Application Type	NDA 203510 SDN 006
Submission Number	SDIV 000
Letter Date	September 20, 2012
Stamp Date	September 21, 2012
PDUFA Goal Date	March 21, 2013
Reviewer Name	Martin P. Nevitt, M.D., M.P.H.
Review Completion Date	February 20, 2013
Established Name	Phenylenhrine Hydrochloride
Established Ivallie	Ophthalmic Solution 2.5% and
	10%
(D	(b) (4)
(Proposed) Trade Name	
Therapeutic Class	α-adrenergic agonist
Applicant	Paragon Bioteck, Inc.
Applicant Priority Designation	Paragon Bioteck, Inc.
Applicant Priority Designation	Paragon Bioteck, Inc. P
Applicant Priority Designation Formulation	Paragon Bioteck, Inc. P Ophthalmic solution
Applicant Priority Designation Formulation Dosing Regimen	Paragon Bioteck, Inc. P Ophthalmic solution One drop of the 2.5% or 10%
Applicant Priority Designation Formulation Dosing Regimen	Paragon Bioteck, Inc. P Ophthalmic solution One drop of the 2.5% or 10% solution instilled at 3 – 5 minute
Applicant Priority Designation Formulation Dosing Regimen	 Paragon Bioteck, Inc. P Ophthalmic solution One drop of the 2.5% or 10% solution instilled at 3 – 5 minute intervals up to a maximum of 3
Applicant Priority Designation Formulation Dosing Regimen	Paragon Bioteck, Inc. P Ophthalmic solution One drop of the 2.5% or 10% solution instilled at 3 – 5 minute intervals up to a maximum of 3 drops
Applicant Priority Designation Formulation Dosing Regimen Indication	 Paragon Bioteck, Inc. P Ophthalmic solution One drop of the 2.5% or 10% solution instilled at 3 – 5 minute intervals up to a maximum of 3 drops Dilate the pupil
Applicant Priority Designation Formulation Dosing Regimen Indication	 Paragon Bioteck, Inc. P Ophthalmic solution One drop of the 2.5% or 10% solution instilled at 3 – 5 minute intervals up to a maximum of 3 drops Dilate the pupil
Applicant Priority Designation Formulation Dosing Regimen Indication Intended Population	 Paragon Bioteck, Inc. P Ophthalmic solution One drop of the 2.5% or 10% solution instilled at 3 – 5 minute intervals up to a maximum of 3 drops Dilate the pupil 2.5% or 10% used in Adults,
Applicant Priority Designation Formulation Dosing Regimen Indication Intended Population	 Paragon Bioteck, Inc. P Ophthalmic solution One drop of the 2.5% or 10% solution instilled at 3 – 5 minute intervals up to a maximum of 3 drops Dilate the pupil 2.5% or 10% used in Adults, 2.5% used in infants less than 1

Table of Contents

1	REC	OMMENDATIONS/RISK BENEFIT ASSESSMENT	4
	1.1 1.2 1.3 1.4	Recommendation on Regulatory Action Risk Benefit Assessment Recommendations for Postmarketing Risk Management Activities Recommendations for other Post Marketing Study Commitments	4 4 4 4
2	INTR	ODUCTION AND REGULATORY BACKGROUND	5
	2.1 2.2 2.3 2.4 2.5 2.6	Product Information Tables of Currently Available Treatments for Proposed Indications Availability of Proposed Active Ingredient in the United States Important Safety Issues With Consideration to Related Drugs Summary of Presubmission Regulatory Activity Related to Submission Other Relevant Background Information	5 5 6 6 7
3	ETH	ICS AND GOOD CLINICAL PRACTICES	7
	3.1 3.2 3.3	Submission Quality and Integrity Compliance with Good Clinical Practices Financial Disclosures	7 8 8
4	SIGN	IFICANT EFFICACY/SAFETY ISSUES RELATED TO OTHER REVIEW DISCIPLINES	8
	4.1 4.2 4.3 4.4 4.4.1 4.4.2 4.4.3	Chemistry Manufacturing and Controls	8 9 9 10 10 10
5	SOU	RCES OF CLINICAL DATA	10
	5.1 5.2 5.3	Tables of Clinical Studies Review Strategy Discussion of Individual Studies	10 12 12
6	REV	IEW OF EFFICACY	12
	$\begin{array}{c} 6.1 \\ 6.1.1 \\ 6.1.2 \\ 6.1.3 \\ 6.1.4 \\ 6.1.5 \\ 6.1.6 \\ 6.1.7 \\ 6.1.8 \\ 6.1.9 \\ 6.1.10 \end{array}$	Indication Methods Demographics Patient Disposition Analysis of Primary Endpoint(s) Analysis of Secondary Endpoints(s) Other Endpoints Subpopulations Analysis of Clinical Information Relevant to Dosing Recommendations Discussion of Persistence of Efficacy and/or Tolerance Effects. Additional Efficacy Issues/Analyses	12 13 13 13 13 18 18 18 19 19 19
7	REV	IEW OF SAFETY	19
	7.1 7.1.1 7.1.2 7.1.3	Methods Clinical Studies Used to Evaluate Safety Adequacy of Data Pooling Data Across Studies to Estimate and Compare Incidence	19 19 21 21

	7.2	Adequacy of Safety Assessments	21
	7.2.1	Overall Exposure at Appropriate Doses/Durations and Demographics of Target Populations	21
	7.2.2	Explorations for Dose Response	22
	7.2.3	Special Animal and/or In Vitro Testing	22
	7.2.4	Routine Clinical Testing	22
	7.2.5	Metabolic, Clearance, and Interaction Workup	22
	7.2.6	Evaluation for Potential Adverse Events for Similar Drugs in Drug Class	22
	7.3	Major Safety Results	22
	7.3.1	Deaths	22
	7.3.2	Nonfatal Serious Adverse Events	22
	7.3.3	Dropouts and/or Discontinuations	23
	7.3.4	Significant Adverse Events	23
	7.3.5	Submission Specific Primary Safety Concerns	23
	7.4	Supportive Safety Results	23
	7.4.1	Common Adverse Events	23
	7.4.2	Laboratory Findings	23
	7.4.3	Vital Signs	24
	7.4.4	Electrocardiograms (ECGs)	24
	7.4.5	Special Safety Studies	24
	7.4.6	Immunogenicity	26
	7.5	Other Safety Explorations	26
	7.5.1	Dose Dependency for Adverse Events	26
	7.5.2	Time Dependency for Adverse Events	26
	7.5.3	Drug-Demographic Interactions	26
	7.5.4	Drug-Disease Interactions	26
	7.5.5	Drug-Drug Interactions	27
	7.6	Additional Safety Explorations	27
	7.6.1	Human Carcinogenicity	27
	7.6.2	Human Reproduction and Pregnancy Data	28
	7.6.3	Pediatrics and Effect on Growth	28
	7.6.4	Overdose, Drug Abuse Potential, Withdrawal and Rebound	28
	7.7	Additional Submissions	28
8	POS	FMARKETING EXPERIENCE	28
9	APP	ENDICES	30
	91	Literature Review/References	30
	92	Advisory Committee Meeting	32
	93	Labeling Recommendations	32
	1.0		

1 Recommendations/Risk Benefit Assessment

1.1 Recommendation on Regulatory Action

NDA 203510 is recommended for approval with the revised labeling identified in this review. The submitted literature references contained in this submission support the use of phenylephrine hydrochloride ophthalmic solution 2.5% and 10% in adults and pediatric patients over one year in age to dilate the pupil. Phenylephrine hydrochloride ophthalmic solution 10% is not recommended for approval for use in pediatric patients less than 1 year old.

1.2 Risk Benefit Assessment

NDA 203510 is being submitted as a 505(b)(2) application. Based on the published clinical literature, the information provided by the applicant supports the approval of this product for the approved indication, i.e. there is a positive benefit to risk ratio.

Systemic adverse reactions to phenylephrine hydrochloride ophthalmic solution are primarily cardiovascular due to its vasoconstriction activity and include palpitation, tachycardia, premature ventricular contractions, hypertension, syncope, myocardial infarction, arrhythmia and fatal subarachnoid hemorrhage. These systemic adverse reactions are more frequent with the 10% solution and more frequent in patients with pre-existing cardiovascular diseases.

Ocular adverse reactions include stinging on instillation, temporary blurred vision and photophobia and conjunctival sensitization.

The 10% solution is not recommended for use in infants less than 1 year old and patients with hypertension where the 2.5% solution should be used due the risk of increased systemic toxicity.

The benefits of using this drug product outweigh the risks for the above indication.

1.3 Recommendations for Postmarketing Risk Management Activities

There are no proposed risk management actions except the usual post-marketing collection and reporting of adverse experiences associated with the use of drug product.

1.4 Recommendations for other Post Marketing Study Commitments

4

There are no recommended Phase 4 clinical study commitments.

2 Introduction and Regulatory Background

2.1 Product Information

Chemical structure of phenylephrine hydrochloride



Chemical Name: C9H13NO2-HCl

Contains:

Active: phenylephrine hydrochloride 25 mg (2.5%); phenylephrine hydrochloride 100 mg (10.0%)

Preservative: benzalkonium chloride 0.01%

Inactives: sodium phosphate monobasic, sodium phosphate dibasic; boric acid, water for injection. Hydrochloric acid and/or sodium hydroxide may be added to adjust pH (6.0-6.4)

2.2 Tables of Currently Available Treatments for Proposed Indications

Cyclomydril (NDA 011663) is a combination ophthalmic solution of phenylephrine hydrochloride 1% and cyclopentolate hydrochloride 0.2% approved for the production of mydriasis that was withdrawn April 30, 1984. Cyclomydril was not withdrawn for safety or efficacy reasons.

PREDNEFRIN[®] Forte eye drops (prednisolone acetate, 1.0% and phenylephrine hydrochloride, 0.12%), for another indication (severe inflammation (non-infectious) of the eye) was withdrawn in 1975.

2.3 Availability of Proposed Active Ingredient in the United States

Phenylephrine is an a-adrenergic receptor sympathetic agonist that has been used for more than 70 years to dilate the pupil in ocular diagnostic, therapeutic and surgical procedures due to its vasoconstrictor and mydriatic action. Phenylephrine was included in the OTC monograph for use as an ophthalmic vasoconstrictor for relief of ocular redness at concentrations of between 0.08% and 0.2%.

NDA 203-826 phenylephrine hydrochloride injection, USP was approved December 12, 2012 and is indicated to increase blood pressure in acute hypotensive states, such as shock and perioperative hypotension.

Phenylephrine hydrochloride ophthalmic solutions, 2.5% and 10%, are currently being marketed and supplied in the US for use as a mydriatic without approved new drug applications.

2.4 Important Safety Issues With Consideration to Related Drugs

There have been rare reports of serious cardiovascular reactions, including ventricular arrhythmias and myocardial infarctions in patients using phenylephrine 10%. These episodes, some fatal, have usually occurred in patients with pre-existing cardiovascular diseases. For this reason, 10% phenylephrine should not be used in patients known to have these risk factors. Phenylephrine 2.5% should be used in these patients.

A significant elevation in blood pressure is rare but has been reported following conjunctival instillation of recommended doses of phenylephrine 10%. The risk is less with phenylephrine 2.5%. Caution should be exercised in infants of low body weight, and patients with hypertension, hyperthyroidism. The post-treatment blood pressure of these patients, and any patients who develop symptoms, should be carefully monitored.

2.5 Summary of Presubmission Regulatory Activity Related to Submission

NDA 203510, phenylephrine hydrochloride ophthalmic solution, 2.5 % and 10% was originally submitted October 19, 2011, and was received on October 21, 2011.

On December 16, 2011, a REFUSAL TO FILE letter was sent that noted:

After a preliminary review, we find your application is not sufficiently complete to permit a substantive review. Therefore, we are refusing to file this application under 21 CFR 314.101(d) for the following reasons:

The NDA does not provide sufficient stability data to establish the stability profile of the drug product over the requested shelf-life. Per ICH Q1A (R2), 12-month long-term and 6-month accelerated stability data for three batches should be provided for us to be able to evaluate the stability of the drug product over the requested shelf-life.

Release data for the two exhibit batches, one each for the two strengths, 2.5% and 10%, have been provided in the NDA but the submission does not provide stability data for these batches. Stability data submitted for the historical batches are inadequate since they were only tested for a few quality attributes. Furthermore, the long-term and accelerated data were generated from different batches which limits evaluating stability of any one batch stored under different conditions.

Additionally, the NDA lacks data on freeze-thaw and weight loss studies.

In addition, we request that you submit patent certifications for the listed drugs to which you refer in your application.

On October 21, 2012, Paragon Bioteck, Inc. re-filed NDA 203510 for the use of phenylephrine hydrochloride ophthalmic solution 2.5% and 10% in adults and phenylephrine hydrochloride ophthalmic solution 2.5% in infants to dilate the pupil (b) (4)

Consistent with the recently issued FDA Guidance for FDA Staff and Industry entitled "Marketed Unapproved Drugs - Compliance Policy Guide: See 440.100 Marketed New Drugs Without Approved NDAs or ANDAs" dated September 19, 2011, Paragon submitted this NDA to help address this unapproved drug product being supplied and marketed as an unapproved product.

NDA 203510 was granted a Priority review at filing to fill an unmet medical need.

2.6 Other Relevant Background Information

Phenylephrine hydrochloride has been the subject of hundreds of clinical trials since its introduction into the marketplace over 70 years ago. From this large volume of clinical trials, several studies that were designed as randomized, masked studies and that contain statistical analysis are reviewed in Sections 5.0 and 6.0 of this Medical Officer's review.

NDA 19-849 for dapiprazole hydrochloride ophthalmic solution, 0.5% was approved on December 31, 1990, with the following indication: th

This NDA 19-849 application was not utilized or referenced in this current new drug application for phenylephrine ophthalmic solution.

3 Ethics and Good Clinical Practices

3.1 Submission Quality and Integrity

This New Drug Application is being submitted as a 505(b)2 application. Paragon Bioteck, Inc. certified that it did not and will not use in any capacity the services of any person debarred under section 306 of the Federal Food, Drug, and Cosmetic Act in connection with this application.

Reference literature reports, surveys, and articles cited in this review are representative of the published literature. There is no evidence that these references refer to trials not conducted in accordance with acceptable clinical ethical standards.

3.2 Compliance with Good Clinical Practices

Reference literature reports, surveys, and articles cited in this review are representative of the published literature. There is no evidence that these references refer to trials not conducted in accordance with acceptable clinical ethical standards.

3.3 Financial Disclosures

This is a 505(b)(2) supplemental application primarily based on literature. In accordance with 21 CFR Part 54, no financial disclosure is appropriate for this application. There are no "covered clinical studies" in this submission.

4 Significant Efficacy/Safety Issues Related to Other Review Disciplines

4.1 Chemistry Manufacturing and Controls

This is a Type 7 NDA for a drug already marketed without an approved NDA. These solutions have been manufactured by the drug product manufacturer (b) (4)

except that the previously manufactured solutions had a (b) (4). The solutions described in this NDA have (b) (4)

. The container-closure system described in this NDA is the same as that previously employed.

The product is a sterile (b) (4) preserved, multi-use solution in opaque white LDPE bottles fitted with dropper tips and caps. The 2.5% solution contains 15 mL per bottle and the 10% solution contains 5 mL per bottle. The composition is as follows:

Component	Function	2.5% Solution	10% Solution
Phenylephrine HCl NaH2PO4, USP Na2HPO4, USP Boric acid, NF	Active (b) (4)	2.5%	10% (b) (4)
Benzalkonium chloride, NF	Preservative	0.01%	0.01%
Sodium hydroxide, NF	pH adjustment	qs	qs
Hydrochloric acid, NF	pH adjustment	qs	qs
Water for injection, USP			(D) (4)

The

^{(b) (4)} 10% solution does not contain boric acid ^{(b) (4)}

so solution does not contain oone acid

The following post-marketing commitments were recommended by ONDQA. Note that the exact wording has not yet been finalized at the time of this review and that these issues are not thought to pose a safety risk.

- Evaluate chiral purity of the drug product: Develop a chiral HPLC method to measure ^{(b) (4)} phenylephrine in the drug product and analyze newly manufactured batches, stability batches until 24-months, and retained samples of drug substance (if available). When sufficient information has been collected, submit a report with numerical data.
- 2) Evaluate leachables present in the drug product: Analyze drug product that has been stored 6 months at accelerated (25C/60% RH) and 24 months long-term (refrigerated) storage conditions for the presence of leachables using a screening analytical method. Use an appropriate control solution for this analysis. Submit a report with numerical data to show the amount of leachables present, if any.

Reviewer's comments:

Clinically in the eye, there is no difference between the ^{(b) (4)} forms of phenylephrine.

4.2 Sterility Assurance

Phenylephrine HCl Ophthalmic solution, 2.5% and 10%, is a topical, ophthalmic preparation of the active ingredient in a (0) (4), preserved, aqueous solution in a multidose dropper bottle. The drug product is preserved with benzalkonium chloride (0.01%).

Refer to Clinical Microbiology review.

4.3 Preclinical Pharmacology/Toxicology

On the basis of the well established use of phenylephrine hydrochloride, the nonclinical safety information is largely based on the comprehensive toxicology testing conducted on phenylephrine hydrochloride by the National Toxicology Program in 1987. No new clinical or nonclinical studies were conducted.

Refer to Pharmacology/Toxicology review.

4.4 Clinical Pharmacology

The applicant did not conduct any clinical pharmacology related studies and did not request the waiver of evidence of in vivo bioavailability or bioequivalence. In accordance with the 21 CFR §320.22(e) – "FDA, for good cause, may waive a requirement for the submission of evidence of

in vivo bioavailability or bioequivalence if waiver is compatible with the protection of the public health", the Clinical Pharmacology review team will grant the waiver of evidence of in vivo bioavailability or bioequivalence to this NDA, considering the extensive clinical experience of the product.

4.4.1 Mechanism of Action

Phenylephrine is an alpha receptor sympathetic agonist used (b) (4) due to its vasoconstrictor and mydriatic action. Phenylephrine possesses predominantly α -adrenergic effects. In the eye, phenylephrine acts locally as a potent vasoconstrictor and mydriatic, by constricting ophthalmic blood vessels and the radial muscle of the iris.

4.4.2 Pharmacodynamics

The ophthalmologic usefulness of phenylephrine is due to its rapid effect and moderately prolonged action; maximal mydriasis occurs in 60-90 minutes with recovery after 5-7 hours.

4.4.3 Pharmacokinetics

The systemic exposure following topical administration of phenylephrine has not been studied. A higher systemic absorption is expected for the 10% solution than the 2.5% solution, and when the corneal barrier function is compromised.

5 Sources of Clinical Data

5.1 Tables of Clinical Studies

See Appendix 9.1 of this review for a list of these literature articles.

Summary of Key Efficacy Studies

Author - date Title		Description
		a) Design
		b) Efficacy
		c) Safety
Gambill 1967	Mydriatic effect of four drugs determined with pupillography	a) 15 subjects (Caucasians) Cross over Infra red pupillography Comparison of effect of
		bright light on pupil diameter change in dark
		adapted eyes Untreated eye used as control
		 b) Tropicamide showed fastest onset most
		effect and shortest duration
		10% PE and Homatropine were similar in
		effect
		Hydroxyamphetamine showed least effect All showed greater efficacy in blue v brown
		eyes
		c) None reported
Haddad 1970	Mydriatic effect of phenylephrine	a) Grp 1 (n=8) crossover (7 day washout)
	hydrochloride	0 1%, 0 25%, 0 5%, 1%, 5%, 10% using IR
		Pupillograph
		Grp 2 1% fresh aqueous solution PE (n=25)
		10% commercial formulation PE (n=25)
		b) Dose response established 10%
		commercial less effective than 10% aqueous
		fresh
		c) No effect on accommodation or IOP A
		dose related rebound miosis seen at 24 hrs
Chawdhary 1984	Mydriatic-use of Phenylephrine (Dose	a) 10%, 5%, 2 5% 1 25% (N=10/group)
	response study)	Double masked Dose response/controlled
		b) Mydriatic dose response 1 25% was
		significantly worse than 2 5% and higher
		c) Safety was dose related 2 5% and 1 25%
		had no effect on pulse and BP whereas 10%
		and 5% did Effect was greater with 10% and
		at 6-8 mins
Yospaiboon 2004	Randomized Double blind Study of	a) N=564 randomized into Group 1 (n=293)
	Phenylephrine 2 5% vs 10% on Pupillary	1% tropicamide and 10% phenylephrine Grp
	Dilation	2 (n=271) 1% tropicamide and 2 5%
		phenylephrine
		b) Statistically significant difference in favor
		of group 1 (10% phenylephrine)
		c) No difference in BP Statistically
		significantly higher HR in Group 1

Pediatric Efficacy Study

Author - date	Title	Description
		a) Design
		b) Efficacy
		c) Safety
Sindel 1986	Comparison of the Pupillary Cardiovascular	a) Randomized
	Effects of Various Mydriatic Agents in	 A) Phenylephrine 2 5%, tropicamide 1 0%
	Preterm Infants	n=10)
		B) Phenylephrine 2 5%, tropicamide 0 5%
		n=10)
		C) Phenylephrine 1 0%, tropicamide 1 0%
		n=10)
		D) Saline (n=4)
		b) Mydriasis in groups A and B was not
		different Group C was less in bright light but
		still > 6 mm
		c) Blood pressure and heart rate change
		significantly less in group C

5.2 Review Strategy

The September 20, 2012, submission was submitted electronically. Subsequent amendments were also submitted in electronically. All literature reports were reviewed.

A literature search conducted by this reviewer failed to identify any additional literature references which were contrary to the information provided or referenced by Paragon Bioteck, Inc. in this application for this indication.

5.3 Discussion of Individual Studies

The key efficacy studies listed in Section 5.1 are based on studies with a control group demonstrating efficacy of phenylephrine in producing mydriasis, in studies where a dose response was used comparing the efficacy of 2.5% and 10% phenylephrine and in studies in children.

This application relies on articles from the published literature, and no new efficacy studies were conducted by the applicant. The Applicant grouped the studies as follows:

 Studies with a control group demonstrating efficacy of phenylephrine in producing Mydriasis (Gambill et al 1967, Haddad 1970, Chawdhary et al 1984, Yospaiboon 2004)
 Studies comparing the efficacy of 2.5% and 10% phenylephrine (Chawdhary et al 1984, Yospaiboon 2004)
 Studies in children (Sindell 1986)

4. Supporting studies (Filho 2007, Ozturk 2000, Tanner 1996, Eyeson-Annan 1998, Paggiarino 1993, Neuhaus 1980)

6 Review of Efficacy

Efficacy Summary

6.1 Indication

The indication is for the use of Phenylephrine Hydrochloride Ophthalmic solution 2.5% and 10% to dilate the pupil ^{(b) (4)}.

6.1.1 Methods

The support for efficacy for Phenylephrine Hydrochloride Ophthalmic solution 2.5% and 10% ophthalmic solution comes from the four studies listed in Section 5.1: Gambill 1967, Haddad 1970, Chawdhary 1984 and Yospaiboon 2004 and the Pediatric Study by Sindel 1986.

See Appendix 9.1 of this review for a list of these literature articles.

6.1.2 Demographics

Key Efficacy Studies

	Gambill study	Haddad study		Chawdhary study	Yospaiboon study
Number of Subjects	15	8	24	40	564
		(Group 1)	(Group 2)		
		First Phase			
		of Study**			
Gender					
Male	8	NR	NR	NR	248
Female	7	NR	NR	NR	316
Age					
Range in years	12 - 38	21-53	All > 50	20 - 40	5 - 87
mean	26.4	NR	NR	NR	51.1
Iris color					
Blue	9	3	NR	-	-
Hazel	3	2	NR	-	-
Brown	3	3	NR	40	564

*NR - not reported

** Group 1 subjects confirmed a dose response curve from 0.1% up to 10% phenylephrine. The dose response began to plateau off at 5% phenylephrine with a complete plateau established at 10% phenylephrine.

Reviewer's comments:

Various reports and observations by clinicians have demonstrated that light colored irides dilate more easily with phenylephrine. Therefore, to study the mydriatic effect of phenylephrine in clinical trials many investigators enrolled a majority of subjects with dark colored irides (the more difficult cases) to demonstrate the dilation effect of the drug. While not preferred, this is acceptable.

6.1.3 Patient Disposition

The efficacy results are based on the all randomized patients enrolled in the four studies. The effect of topical phenylephrine hydrochloride ophthalmic solution 2.5% and 10% occurs nearly immediately; therefore all subjects that were randomized and enrolled into the studies were evaluated.

- 6.1.4 Analysis of Primary Endpoint(s)
- 6.1.4.1 Efficacy studies using the consensual light reflex to demonstrate phenylephrine's ability in producing mydriasis

Gambill 1967 Study and Haddad 1970 Study – Group 2

The purpose of the Gambill 1967study was to compare, with the aid of accurate measurements, the mydriasis produced by four drugs: 0.5% tropicamide, 2% homatropine hydrobromide, 1% hydroxyamphetamine hydrobromide, and 10% phenylephrine hydrochloride. In each patient, after instillation of the drug in the left eye (the right eye served as the control), the pupillary diameters at maximal constriction of both eyes as a response to a light flash of constant intensity and duration were measured every two minutes for 40 minutes, then every five minutes for 20 minutes. At any given time after instillation of the drug, the difference in constriction between the two eyes (less than any initial anisocoria) was then taken as a measure of the degree of mydriasis.

The purpose of the Haddad 1970 study was to determine the dose-response curve for phenylephrine HCI in a group of young, normal subjects and to evaluate the mydriatic effect of this drug in a group of older subjects in order to better characterize the effects of this drug on the iris. For both groups, after a baseline tracing was made, two drops of the drug solution being evaluated were instilled into the right eye of each subject (the left eye served as the control). The study endpoints were the difference in pupillary diameter of the two eyes at maximal constriction produced by light stimulation at appropriate time intervals.

Group 1: all subjects were tested with each concentration; at least seven days elapsed between dosing when a solution stronger than 1% was used. Pupillary size and response to the standard light stimulus were recorded at 15-minute intervals for 90 minutes and then hourly until recovery from mydriasis had occurred. The tracing was repeated at 24 hours after instillation of the drug.

Group 2: The drug was instilled after an initial tracing, and a repeat tracing was recorded at 75 minutes, the average time for mydriasis to occur as determined in Group 1. Pupillary size and reactivity were again recorded at 24 hours after initial instillation of the drug; the same drug solution then instilled and a final tracing obtained 75 minutes later.

(10% phenylephrine)								
All SubjectsLight IridesDark Irides(N=15)(N=9)(N=6)								
Amount of maximal pupil mydriasis (mm)*								
Mean	2.42	2.69	2.01					

Gambill Study

*Measured with infrared pupillography to evaluate the difference in pupil size between treated and untreated eyes of a subject when a light stimulus is applied to the eyes in dim illumination

Haddad Study – Group 2				
	1.0 %	10%		
	phenylephrine	phenylephrine		
	(N=12)	(N=12)		
Amount of maximal pupil mydriasis (mm)*				
Mean and SD	3.4 (± 0.35)	3.57 (± 0.02)		

Haddad	Study -	Group	2
--------	---------	-------	---

*Measured with infrared pupillography to evaluate the difference in pupil size between treated and untreated eves of a subject when a light stimulus is applied to the eyes in dim illumination

Reviewer's comments:

The degree of mydriasis was determined by measuring the difference in pupillary responses of the two eyes to a light stimulus when the drug has been instilled in only one eye. Normally both pupils constrict equally when one eye alone is stimulated.

These studies demonstrate that the eyes dosed with phenylephrine remain dilated approximately 2.5 - 3.5 mm more than the contralateral eve when stimulated by a light reflex. These results confirm the ability of phenylephrine to dilate the pupil.

6.1.4.2 Efficacy studies comparing various concentrations of phenylephrine to produce mydriasis

Chawdhary 1984 Study and Yospaiboon 2004 Study

The purpose of the Chawdhary 1984 study was to study the effects of various dilutions of phenylephrine hydrochloride ophthalmic solution in terms of effective mydriasis and cardiovascular effects in an Indian population having brown irides. Subjects were divided into 4 groups of 10 patients each. Fresh aqueous solutions of phenylephrine hydrochloride were prepared in concentrations of 10%, 5%, 2.5% and 1.25%. The drugs were coded and used randomly. One drop of the drug was put every 1 minute three times in the lower conjunctival culde-sac. Puillary sizes at 2, 4, 6, 8, 10, 15, 20, 30, 50 and 70 minute were measured.

The purpose of the Yospaiboon 2004 study was to compare the safety and efficacy of phenylephrine 2.5% versus 10% on pupillary dilation for dark irides. All patients first received one drop of 1% tropicamide and 30 minutes later one drop of 10% or 2.5% phenylephrine by simple random allocation. Pupil measurement was performed immediately before 1% tropicamide, 30 minutes after 1% topicamide (before 10% or 2.5% phenylephrine) and 30 minutes after 10% or 2.5% phenylephrine. Systolic and diastolic blood pressure and heart rate were also measured before and 30 minutes after 10% phenylephrine or 2.5% phenylephrine.

11 40								
	Mean and standard deviation of pupil size in mm at maximal dilation							
	1.2	5 %	2.5	5 %	5	%	10%	
	phenyl	ephrine	phenyl	ephrine	phenylephrine		phenylephrine	
	(N=	=10)	(N=	=10)	(N=10)		(N=10)	
Amount	Baseline	Maximal	Baseline	Maximal	Baseline	Maximal	Baseline	Maximal
of	Pupil	Pupil	Pupil	Pupil	Pupil	Pupil	Pupil	Pupil
maximal		_		_	_	_	_	_
pupil								
mydriasis								
(mm)*								
Mean	4.1 ±	$5.8 \pm$	$4.2 \pm$	$7.2 \pm$	$4.3 \pm$	$7.65 \pm$	$4.2 \pm$	$8.2 \pm$
and SD	0.22	0.27	0.27	0.75	0.27	0.22	0.27	0.27

Chawdhary Study	
N=40	

Yospaiboon Study* N=564

Mean and standard	deviation a	of nunil	size in mn	at maximal dilation
Wicall and Standard	ueviation (or pupir	SIZE III IIIII	i at maximal unation

	2.5 %		10%					
	phenylephrine			phenylephrine				
		(N=	271)		(N=293)			
Amount	Baseline	Maximal	Baseline	Maximal	Baseline	Maximal	Baseline	Maximal
of	Pupil	Pupil	Pupil	Pupil	Pupil	Pupil	Pupil	Pupil
maximal	(OD)	(OD)	(OS)	(OS)	(OD)	(OD)	(OS)	(OS)
pupil								
mydriasis								
(mm)*								
Mean	$4.45 \pm$	$7.17 \pm$	$4.32 \pm$	$7.07 \pm$	$4.43 \pm$	$7.58 \pm$	$4.31 \pm$	$7.6 \pm$
and SD	1.0	1.04	0.92	1.06	1.13	0.96	0.95	1.03

* All eyes had also received one drop of 1% tropicamide

Reviewer's comments:

These results confirm the ability of phenylephrine to dilate the eye. Baseline pupillary dilation ranged from 4.1 to 4.4 mm while after instillation of phenylephrine pupillary dilation ranged from 7.0 to 8.2 mm.

6.1.4.3 Efficacy study in newborns demonstrating phenylephrine's ability to produce mydriasis

Sindel 1986 Study

The purpose of the Sindel 1886 study was to compare the safety and efficacy of the combination of mydriatic drops (phenylephrine 2.5% plus 0.5% tropicamide plus 0.5% cyclopentolate) with two other combinations of mydriatic drops (phenylephrine 2.5% plus 1.0% tropicamide, and phenylephrine 1.0% plus 1.0% tropicamide) in preterm infants.

Infants scheduled for routine screening ophthalmoscopy (for retinopathy of prematurity) were eligible for study. They were selected if their cardiovascular status was stable, and one of the principle investigators was available to perform the measurements. 30 infants were randomly assigned to receive one of three single drop mydriatic solutions prepared. Four additional infants received only saline solution and served as controls (investigators not blinded in this group). Each infant received one drop of the solution in each eye, and a second drop, five minutes later. Pupillary dilation was measured with a metric ruler by direct observation at one hour. Blood pressure (BP) and heart rate (HR) were monitored immediately prior to the instillation of the drops and at five-minute intervals, for 60 minutes. For each subject, both eyes were included and evaluated in the study.

(N=34)								
	Phenylepl	hrine	Phenylephrine		Phenylephrine		Saline only	
	2.5% and		2.5% and		1.0% and			
	1% tropic	amide	0.5% tropicamide		1.0% tropicamide			
	(N=10)		(N=10)		(N=10)		(N=4)	
Age at	53	3.9	52	2.9	52	2.3	54	4.0
study								
(days)								
Birth	1022	± 226	1115	± 281	1110	± 317	980 :	± 155
weight								
(grams)		-						
Amount	Baseline	Maximal	Baseline	Maximal	Baseline	Maximal	Baseline	Maximal
of	Pupil	Pupil	Pupil	Pupil	Pupil	Pupil	Pupil	Pupil
maximal								
pupil								
mydriasis								
(mm)*								
	$2.8 \pm$	$7.4 \pm$	$3.0 \pm$	$7.3 \pm$	$2.9 \pm$	7.1 ±	$2.9 \pm$	$2.9 \pm$
Mean	0.8	0.5	0.6	0.4	0.6	0.6	0.2	0.2
and SD								

Reviewer's comments:

The ability of phenylephrine to dilate the eye is also demonstrated in neonates. Baseline pupillary dilation ranges from 2.8 to 3.0 mm while after instillation of phenylephrine pupillary dilation ranges from 7.1 to 7.4 mm. See also Section 7.4.5 of this review for safety information in neonates.

6.1.4.4 Dark versus Light Irides

(b) (4)

Per Gambill 1967, computed mydriasis-time curves and the average experimental data for homatropine in subjects with light and dark irides in the study were constructed. It was reported, "...essentially the same results were found for the other three mydriatic drugs" (which included 10% phenylephrine). Per Haddad 1970, "...significant differences in degree of mydriasis occur with variations in iris pigmentation. Of our subjects, those with hazel irides consistently developed the least mydriasis while those with blue irides developed the greatest."

Reviewer's comments:

There is evidence that 10% phenylephrine has slightly higher treatment effects compared with 2.5% concentration in patients with dark irides,

6.1.5 Analysis of Secondary Endpoints(s)

Not applicable.

6.1.6 Other Endpoints

Not applicable.

6.1.7 Subpopulations

The overall age range of patients from the key efficacy studies was 5-87 years. Neonates were evaluated separately for safety and efficacy. Based on a comparison across studies, the effectiveness results do not appear to vary with age.

In general, more females than males participated in these studies. None of the studies examined the effects of gender on the effectiveness outcome.

None of the demographic factors described appeared to correlate with any specific efficacy outcome.

6.1.8 Analysis of Clinical Information Relevant to Dosing Recommendations

See Section 6.1.4 of this review. The studies support a dosing regime of 2.5% and 10% phenylephrine solution instilled at 3-5 minute intervals up to a maximum of 3 drops per eye in patients aged 1 or older and 2.5% phenylephrine in pediatric patients < 1 year old.

6.1.9 Discussion of Persistence of Efficacy and/or Tolerance Effects

The drug's maximal effect occurs in 60-90 minutes with recovery after 5-7 hours.

6.1.10Additional Efficacy Issues/Analyses

None.

7 Review of Safety

Safety Summary

7.1 Methods

7.1.1 Clinical Studies Used to Evaluate Safety

A review of the published literature shows there are a substantial number of publications describing the safety of the use of phenylephrine hydrochloride for topical ophthalmic use at concentrations ranging from 1 % to 10%. Key safety articles with their summaries are listed below:

See Appendix 9.1 of this review for a list of these literature articles.

¹⁹

Alian Display Di			
Allison: 1990 Reveal of Mydisis/ Dippratole 9.95 anjects. simila singlet, mediation Dippratole: treatment cyc. All cycs necticed 1% Tory and 2.95 fr.87. Brown 1980 Lad. of Side Effects. From Typeluly Administered (MyDenset) 9.9 anjects. simila singlet, mediation Dippratole: Typeluly Administered (MyDenset) 9.9 anjects. simila singlet, mediation Dippratole: Typeluly Administered (MyDenset) Brown 1980 Lad. of Side Effects. From Typeluly Administered (MyDenset) 9.0 anjects. simila singlet, MyDenset (MyDenset) 9.0 anjects. Singlet (MyDenset) Streams 1980 Systemic of Effects of Signal placylphatics (10%) 9.0 anjects. Singlet (MyDenset) 9.0 anjects	Authors	Study title	a) Design b) Efficacy data c) Safety data
Intern 1990 Lot of Side Effects from Tepology Administered (Not Pencyleptice Systops A Controlled Stady a) Controlled Condent and de TP, 1994; = 100; Tep 1974; = -59 (Not Pencyleptice Systops A Controlled Stady Summary 1975 Systemic effects of topical plexyleptice (10%) a) Marking the systemic effects of topical plexyleptice (10%) a) Marking the systemic effects of topical plexyleptice (10%) Choudhary 1594 Mydrains one of Pencyleptine (a doe response composite) a) Marking the systemic effects of topical plexyleptine (10%) Choudhary 1594 Mydrains one of Pencyleptine (a doe response composite) a) Mydrains one of Pencyleptine (a doe response composite) a) Mydrains one effects of topical plaxyleptine (10%) Chain 1594 Bir 1994 conservation and playing effects of topical four plant of topical four marks of the optical 25% near sign 10% fram 213% fram ser significant in non logertensive. (20% of the marks 5 Mark or 23% near 23% near significant in non logertensive. (20% of the mark 5 Mark or 23% near significant in non logertensive. (20% of the mark 5 Mark or 23% near significant fram topical plant marks 1 Mark or 23% near significant fram topical plant marks 1 Mark or 23% near significant fram topical plant marks 1 Mark or 23% near significant fram topical plant marks 1 Mark or 23% near significant fram topical plant marks 1 Mark or 23% near significant fram topical plant marks 1 Mark or 23% near significant fram topical plant marks 1 Mark or 23% near significant fram topical plant marks 1 Mark or 23% near significant fram topical plant mark or 23% near significant fram topical plant mark or 23% nean 10% PF. System	Allinson 1990	Reversal of Mydiasis/ Dipiprazole	a) 50 subjects, within subject, randomized Dipiprazole treatment eye. All eyes received 1% Trop and 2.5% PE. b) 5mm mydriasis on T+PE (p=0.01<0.05) Reduced post D by over 3 mm in two hours and completely in 24 hrs. c) BP and Pulse, IOP. No sig diff. No data given
Name Process10.3 desp.2 langs space in both cyrs. No data on effactyA Consolied Stap3) desp.2 langs space in both cyrs. No data on effactySamatray 1075Systemic effects of typical photylephine (10%)10% PF O They found decritions of P4 and Its 3DB and 10~-30mall got SBPChordhary 1084Mydrint-iss-an of Phenylephine (10%)10% PF O They found decritions of 144 and Its 3DB and 10~-30mall got SBP of 146 and 144 and 158 and 144 and 156 an	Brown 1990	Lack of Side Effects From Tonically Administered	a) Controlled Double masked PE 10% n=100 Tran 1% n=50
A ConsolieO Site afference between the PE and T on DBP. SBP or PolicSmattary 1975Systemic effects of topical plexyleptine (10%)O Site afference between the PE and T on DBP. SBP or PolicChowdhary 1944Myfrinsis-ase of Phenyleptine (a door response concept) of Site afference between state SBP and 10%-SSP. 35% SBP (5%-19) group) Doahte marked. Doer response controlled Myfrindic der exponse state SBP and 10%-SSP. 35% SBP (3%) SBP	Diowa 1200	10% Deenvlenhring Evedrone	h) 2 drone 2 mine anart in both aver. No data on afficacy
Authors Status		A Controlled Study	c) No difference between the PE and T on DBP. SBP or Pulse
Summary 1979 System criters of topical plexysplane (UPS) a) 10% Pk. Chordbary 1984 Mprinsis-ene of Renyrlephrine (a dox response concerned) a) 10% SN, 25% 12% (N=VB georg) Double maked. Disc response concerned) Chordbary 1984 Pff: eye dowp is optimalini surgery – a clinical study of Mynica dow response. Sign (17 bettern 25% and 12%) (-2.5% and 10% (-5.0% georg) model maked. Disc response controlled) Chin 1994 Pff: eye dowp is optimalini surgery – a clinical study of Mynica dow response. Sign (17 bettern 25% and 12%) (-2.5% and 10% (-5.0% georg) model in (5% the 25% and 10%) (-5.0% georg) model in (5% the 25% and 10% (-5.0% georg) model in (5% the 25% and 10% (-5.0% georg) model in (5% the 25% and 10% (-5.0% georg) model in (5% the 25% and 10% (-5.0% georg) model in (5% the 25% and 10%) (-5.0% georg) model in (5% the 25% and 10% (-5.0% georg) model in (5% the 25% mod 10% (-5.0% georg) model in (5%			to the and the reader of the reader of the reader
Clowalay 1981 Clowalay 1984 Clowalay 1984Mydniksis-use of Plenykplanie (a dose response concerne) and Plenykplanie 23% and 123%. 	Samantary 1975	Systemic effects of topical phenylephrine (10%)	a) 10% PE. c) They found elevations of 10-40 mmHg SBP and 10=-30mmHg of SBP
b) Mydiat doe response. Sig diff? there 2,5% and 12,5% c) Jaky is doe relation of effect and by wherea 10% and 5% diff. More is with 10% and 4 6 8 miss. Clin 1994 Elery edops in ophthalmic surgery – a clinical study and state is a miss. Since (~20), 25% (~2)° and 10% (m.10/PE and wydriscyl. undergoing eatmert is a 10% of the 2.5% and 2.5% mare is 20% more by and 10% (m.10/PE in and ydriscyl. undergoing eatmert is a 10% of the 2.5% mare is 20% more by and 10% (m.10/PE in and ydriscyl. undergoing eatmert is 10% of the 2.5% mare is 20% more by and 10% (m.10/PE in and 10% more is a 10% of the 2.5% mare is 20% more by and 10% (m.10/PE in a 2.5% mare is 20% more by and 10% (m.10/PE in a 2.5% mare is 20% more is a 10% of the 2.5% mare is 10% more is a 10% of the 2.5% mare is a 10% of the 2.5% more is 10% of the 2.5% more in the 2.5% more is 10% of the 2.5% more in the 2.5% more is 10% of the 2.5% more in the 2.5% more is 10% of the 2.5% more in the 2.5% more is 10% of the 2.5% more in the 2.5% more is 10% of the 2.5% more in the 2.5% more is 10% of the 2.5% more in the 2.5% more is 10% of the 2.5% more in the 2.5% more is 10% more in the 2.5% more is 10% more is 10% more in the 2.5%	Chowdhary 1984	Mydriasis-use of Phenylephrine (a dose response concept)	a) 10%, 5%, 2.5% 1.25% (N=10/group) Double masked. Dose response/controlled
10 slately is observation 2.3% and 1.3% had on effect on pale and BP wherean 10% and 5% dial.Clin 1994Reference in pythalatic supery - a clinical study of cellion scale in scale in a scale in the PE groups more sig in 10% than 2.5% more significant in non hypertensive 10% of fices of the PE groups more sig in 10% than 2.5% more significant in non hypertensives. 10% of 10% and 3% on 2.5% more significant in non hypertensives. 	account of the second second	n all faith ann ann an ann an ann an 1970 ann an 1970. Bhannach ann 1960 ann an 1970 ann an 1970 ann an 1970 a	b) Mydiatic dose responseSig diff ? between 2.5% and 1.25%
Glui 1994 Rudowickline effektion Subject wated, Saline (wrb, 2,5% (wrb, 29) and 10% (wrb, 100) File and updise); undergoing estatuation is unappropriate with a spin and sp			c) safety is dose related. 2.5% and 1.25% had no effect on pulse and BP whereas 10% and 5% did. .More so with 10% and at 6-8 mins.
and by the presence of the pre	Chin 1994	PE eye drops in ophthalmic surgery - a clinical study of	a) Double masked. Saline (n=30), 2.5% (n=29) and 10% (n=30)PE and mydriacyl. undergoing cataract
b) b) cellicacy data (1) light CPI be the PE proper surve sign in 094 han 2.5% more significant in non hypertensives. 10.5% of 10% and 3% to 2.5% required hypotensive terment.1) libbo 20072.5% and 10% in healthy voltnetces. In Portigones with an Equilab abstract0.1 Case controlicat conductor domose study of 2.5% and 10% FE in 2.81V/S 		cardiovascular effects.	surgery 50% were hypertensive
c) Higher PP in the PE groups more sign 10% Har 2-5% mer displicant in no hypertensives. 10.3% of 0.4% merce displication on hypertensives. 10.3% of 0.4% merce displication of the PE groups more sign 10% har 2.5% merce displication of the PE groups more sign 10% har 2.5% merce displication. 2.5% merce displication. 3.5% displication. <b< td=""><td></td><td></td><td>b) No efficacy data</td></b<>			b) No efficacy data
Internation 10.3% of 10% and 3% on 2.5% required hypotenety returned. 13/tho 2007 Cadrowscentar and papulary effects of topical Ophinhama, 30 Case control 187 and 10% Fin 28 HV/s 30 Case control 187 and 10% Fin 28 HV/s Malhotra 1998 Comparison of endiovascular effects 02 5% and 10% Fin 28 HV/s 30 Net 50 AUX Malhotra 1998 Comparison of endiovascular effects 02 5% and 10% Fin 28 HV/s 30 Net 50 AUX Synons 1997 Lerer to the Editor Review phylicitation (not 200% phylicitation of BP and public 10% pherylephrine phys 1% tropicamide (n=126) vs a 1% tropicamide (n=10) Authors Study title Comparison of BP and public 10% pherylephrine phys 1% tropicamide (n=126) vs a 1% tropicamide (n=10) Authors Study title Delage Delage No endition and Study of Pherylephrine 2.5% vr Pherylephrine 10% (n=271). Both groups received 1% tropicamide (n=100 NO Yoganboo 2004 Review phylicine 0.5% or of 21% pherylephrine 10% or of 21% pherylephrine 10% or of 21% pherylephrine. Study data Yoganboo 2004 Systemic reactions to topical epinylephrine and pherylephrine. Study data Yougaboo 2004 Systemic reactions to topical epinylephrine epinylephrine. Study data Yougaboo 2004 Systemic reactions to topical epinylephrine phylephrine in You or of 21% upinylephrine.			c) Higher BP in the PE groups more sig in 10% than 2.5% more significant in non hypertensives.
Hilbs 2007Calco controlled rankowarder dovors they of 25% and 10% PE in 28 HV/s b 28% and difference in system (Effer p-OD 0.015/05 0.028 c) on difference in system (2007 or 10% PE int 12% PL multiple ton SSD between them c) on difference in system (2007 or 10% PE int 12% PL multiple ton SSD between them c) on difference in multiple ton SSD between them 			10.3% of 10% and 3% on 2.5% required hypotensive treatment.
12. Set wall 01% in beiling volumeters. In Portuguese win an English abstract19. Set sig difference in surfact (2) on difference in suffact (2) both cause an increase in SBP 14.1 - 18.9 multify but no SSD between themMilhoirs 1998Comparison of cardiovascular effects of 2.5% and 10% PE (3) both cause an increase in SBP 14.1 - 18.9 multify but no SSD between themSymons 1997Letter to the Editor With response from Tunner.Previse publication (1) both cause an increase in SBP 14.1 - 18.9 multify but no SSD between themAuthorsSuboy titlePrevise publication (1) both date on mydrinsis presented (2) both dates an increase in SBP 14.1 - 18.9 multify but no SSD between themAuthorsSuboy titlePrevise publication (1) both date on mydrinsis presented (2) both datesYopauboon 2004Randomized Doubh-Mind Study of Phenylephrine 2.5% vor (1) phenylephrine 10% (no c71). Both groups precisived 17% (sorgar) (sorgar) part precisived 17% (sorgar) part precisived 17% (sorgar) (sorgar) part precisived 17% (sorgar) (sorgar) (sorgar) (sorgar) (sorgar)Latter by Comparison difference on part precisived 17% (sorgar) (sorgar)(sorgar) (sorgar) (sorgar) (sorgar) (sorgar)Latter by Comparison difference free free free free free free free fr	Filho 2007	Cardiovascular and papillary effects of topical Ophthalmic	a) Case controlled randomized crossover study of 2.5% and 10% PE in 28 HV's
In Portuguese with an Englaba abstractc) no difference in safetyMalhotra 1998Comparison of cardiovascular effects of 2.5% and 10% TPb) X~54, DM, Randomized 0.25% or 10% PE and 1% Trop. In subjects without CV disease history. c) bota case in increase in SUP 14. J = 18.9 mmlift but as SSD between themSymons 1997Letter to the Editor With response from Tamer.Review publication (a Comparison of DP and puble 10% phenylephrine plus 1% tropicamide (n=126) vs a 1% tropicamide (n=140) b) No data on mydrinsis presented (b) No data on mydrinsis presented (c) No data on Mydrinsi Develophrine 10% (n=271). Both groups received 1% tropicamide (c) Sufference on pale rate (c) No Dot on SID on SID or S	and a second	2.5% and 10% in healthy volunteers.	b) Stat sig difference in mydiatic effect p=OD 0.015/ OS 0.028
Milliotra 1998 Comparison of cardiovascular effects of 2.5% and 10% PE a) N=54. DM, Radomized 0.25% or 10% PE and 1% Trop. In subjects without CV disease history. Symons 1997 Letter to the Editor. a) N=54. DM, Radomized 0.25% or 10% PE and 1% Trop. In subjects without CV disease history. Symons 1997 Letter to the Editor. Review publication a) Comparison of P and public 10% phenylephrine plus 1% tropicamide (u=126) vs a 1% tropic		In Portuguese with an English abstract	c) no difference in safety
Number 1998 Comparison of canorysecure effects on 2.9% and 10% Pro 10 NS-S1, DS, Rammerke 0.25% of 10% Pr 11.3 – 18.8 mm Hg in the SD between them Symons 1997 Letter to the Edior Review publication Review publication Number 10% Study title Review publication Review publication Authors Study title No data on mydraks presented () Stefy data Yoganboar 2004 Randomized Double-Mild Study of Phenylephrine 2.5% (n -253) (v phenylephrine 10% (n -271). Boh groups received 1% tropicamide () Stefy data Yoganboar 2004 Randomized Double-Mild Study of Phenylephrine 2.5% (n -253) (v phenylephrine 10% (n -271). Boh groups received 1% tropicamide () Phenylephrine 10% nor patilary dilatation Lansche RK 1966 Systemic reactions to topical epinephrine and phenylephrine () Staff and anter rep-0.005 tut not SBP of DBP. Lansche RK 1966 Systemic reactions to topical epinephrine epinhaline: () Contributing factors discussed. Staff and the rep-0.055 tut not SBP of DBP. Lansche RK 1966 Systemic reactions to topical epinephrine and phenylephrine () Phenylephrine Staff and the reaction and sequere phons for the reaction of the phenylephrine () Staff and the reactis of the phenylephrine () Staff and the	Mallione 1000	Comparison of earliest solar offerts of 2 fe/ and 100/ DF	A N=54 DM Bandamind & 266 as 100 DF and 10 Team to address without CV discuss bistory
Symmes 1997Letter to the Editor With response from Tumer.Review publication and public 10% phenylephtine phis 1% tropicamide (n=12.0) w. at 1% tropicamide (n=14.0) No difference in mean BP but significant difference on the percent of subjects with 30mm Hg matchingAuthorsSolv titlea) Design Difference in mean BP but significant difference on the percent of subjects with 30mm Hg matchingYoyaubooz 2004Randomied Double-Mind Study of Phenylephtrine 25% (n=23) vs phenyleph	Mainotra 1998	during ophthalmic surgery	 a) N=54, DM, Randomized, 0.25% of 10% PE and 1% 1rop. in subjects without CV disease instory. c) both cause an increase in SBP 14.1 – 18.9 mmHg but no SSD between them
Number of the sequence from Tammer.a) Comparison of PP and pube 10% plenylephrine plus 1% tropicamide (n=12.6) vs a 1% tropicamide (n=12	Symons 1997	Letter to the Editor	Review publication
Image: Control of the second		With response from Tanner.	a) Comparison of BP and pulse 10% phenylephrine plus 1% tropicamide (n=126) vs a 1% tropicamide
b) No data on mydriasis presented c) No data on mydriasis presented 		2000 C-0089-5500 C-0010 C-021021	(n=14)
InstantianInstantianInstantianNumberNo difference in men PP but significant difference on the percent of subjects with 30mm Hg nutration in BP.AuthorsStudy titlea) Design b) Efficacy data () Safety dataYospaiboon 2004Randomized Double-blind Study of Phenylephrine 2.5% (n 293) vs phenylephrine 10% (n-271). Both groups received 1% tropicantide. b) Phenylephrine 10% nor effective than 2.5% with significant difference between groups for the amount of additional dilation in the ropicantide p-0.001. (Significant difference on public net topicantide p-0.001. (Significant difference on public net p-0.0051 that S1BP or DBP.Lansche RK 1966Systemic reactions to topical epinephrine and phenylephrine phenylephrine () Significant difference on public net spie 0.0051 that S1BP or DBP.Lansche RK 1976Possible adverse effects from topical ocular 10% phenylephrine.Solodky 1972Hypertension following 10% phenylephrine ophthalmot of Phenylephrine inter DP-0.0051 that S1BP or DFP.Solodky 1973Acute Systemic Hypertension after conjunctival institlation of Phenylephrine Hydrochloride (neurs) in ophthalmology and had subarchnoid blener/hage in a 35 yo. A cotton wick coded in 10% phenylephrine instende in and had subarchnoid blener/hage in a 35 yo. A cotton wick coded in 10% phenylephrine instende in and had subarchnoid blener/hage in a 35 yo. A cotton wick coded in 10% phenylephrine increased BP (69F, 3mth F, 62 M)McReynolds 1956Use of phenylephrine hydrochloride (neurs) in ophthalmology and had subarchnoid blener/hage in a 35 yo. A cotton wick coded in 10% phenylephrine instender and had subarchnoid blener/hage in a 35 yo. A cotton wick coded in 10% phenylephrine instender and had subarchnoid blener/hage in a 35			b) No data on mydriasis presented
Internation in BP. Authors Study tille a) Design b) Efficacy data o) Safety data Yospaihoon 2004 Randomized Double-Mind Study of Phenylephrine 2.5% vs 10% on pupillary dilatation a) Phenylephrine 2.5% (n=323) vs phenylephrine 10% (n=271). Both groups received 1% tropicamide. b) Phenylephrine 10% more efficace than 2.5% with significant difference between groups for the amount of additional dilatation after tropicamide pebolo o) Significant difference on pulse rate p=0.005 but not SBP or DBP. Lansche RK 1966 Systemic reactions to topical epinephrine and phenylephrine phenylephrine Case reports of 2 ubjects 40F had a headsche anged out after 2% epinephrine, 57M experienced increased BP and HR and fainting after a single drop of 10% phenylephrine. Contributing factors discussed. Soloky 1972 Hypertension following 10% phenylephrine ophthalmo: of Phenylephrine Case reports of subjects of subjects or subjects of subjects of subjects or subjects of subjects of subjects sequencing increased BP (69F, 3mH F, 62 M) Witensky 1973 Active Systemic Hypertension after conjunctival instillation of Phenylephrine Hydrochloride (acos-synephrine Hydrochloride) in ophthalmology Case report: BP went from 150/100 to 270/170 after proparacine one drop and three drops 10% phenylephrine in dynocolloride (acos-synephrine Hydrochloride) in ophthalmology Heath 1939 Lise of phenylephrine hydrochloride (acos-synephrine Hydrochloride) in ophthalmology Phenylephrine (hydrochloride in the reports) in slightly in about SS% and slightly increased in 2% (Criterion was ± 4 turn Hig was no change) N=60. <td></td> <td></td> <td>c) No difference in mean BP but significant difference on the percent of subjects with 30mm Hg</td>			c) No difference in mean BP but significant difference on the percent of subjects with 30mm Hg
AuthorsStudy tillea) Design b) Effects gata c) Safely dataYospaboo 2001Radomized Double-bind Study of Phenylephrine 2.5% (u-233) vs phenylephrine 10% (u-271). Bod groups received 1% tropicamide phenylephrine 10% more effective than 2.5% with significant difference between groups for the amount of additional dilatation and tropicamide p-0.001 c) Significant difference on puls rate p-0.005 but not SBP or DBP.Lansche RK 1966Systemic reactions to topical epinephrine and phenylephrineCase reports of 2 subjects 40F had a headache and passed out after 2% epinephrine. 57M experienced increased BP and IR and fainting after a single drop of 10% phenylephrine. Countrbuing factor Studyets 40F had a headache and passed out after 2% epinephrine. Countrbuing factor Studyets of subjects experiencing increased BP (69F, 3mt F, 62 M)Solosky 1972Osvibbe adverse effects from topical ocular 10% benylephrine3 case reports of subjects of subjects experiencing increased BP (69F, 3mt F, 62 M)Wilensky 1973Acute Systemic Hypertension after conjunctival instillation of Phenylephrine information on edrop and three drops 10% phenylephrineCase reports BP went from 150/100 to 270/170 after propancaine one drop and three drops 10% phenylephrine instend in lower of de sax to induce distantion and separate posterior synechiae. BP went from 118/68 to 230/130 and had subarchnoid bleend had advarchnoid bleendBiggs 19591be effec	o s	· · · · · · · · · · · · · · · · · · ·	fluctuation in BP.
AuthorsStudy tilePicega b Efficacy data c Safery dataYospaiboo 2004Randomized Double-bind Study of Phenylephrine 2.5%a) Phenylephrine 2.5% (ref) subjects than 2.5% with significant difference between groups for the annout of additional diatation after tropicamice p-0.001 c) significant difference on posible and study of Phenylephrine 2.5%a) Phenylephrine 10% more effective than 2.5% with significant difference between groups for the annout of additional diatation after tropicamice p-0.001 c) significant difference on posible and the tropicamice p-0.001 c) significant difference on posible and the study of DPBPLamsche RK 1966Systemic reactions to topical epinephrine and phenylephrine phenylephrine 10% more effective than 2.5% with significant difference on passed out after 2% epinephrine. 57M experienced increased BP and HR and fainting after a single drop of 10% phenylephrine. 57M experienced increased BP and HR and fainting after a single drop of 10% phenylephrine. 57M experienced increased BP and HR and fainting after a single drop of 10% phenylephrine. 57M experienced increased BP and HR and fainting after a single drop of 10% phenylephrine. 57M experienced increased BP and HR and fainting after a single drop of 10% phenylephrine. Contributing factor sitesced.Wilensky 1973Apstermic Hypertension after conjunctial instillutiona case report: BP went from 150/100 to 270/170 after proparacine one drop and three drops 10% phenylephrine Hypertension following up on panel and abarachinoid bleen and separate posterior synchaite. BP went from 115/160 to 250% if phenylephrine instered in and abarachinoid bleen and separate posterior synchaite.McReynolds 1956Lead figure on phenylephrine Hypertension and separate posterior synchaite. BP went from 115/160 to 250% if phenylephrine 10% for en			
IndicationDefinition of a start of a star			
InterfactInterfactInterfactYogaiboon 2004Randomized Double-bind Study of Phenylephrine 2.5% (no.293) vs penylephrine 10% (no.271). Both groups received 1% tropicamide. b) Phenylephrine 10% more effective than 2.5% with significant difference between groups for the annount of additional dilation after tropicamide p-0.001. c) Significant difference on pulse rate p-0.005 but not SBP or DBP.Lamsche RK 1966Systemic reactions to topical epinephrine and phenylephrineCase reports of 2 subjects 40F had a headsche and passed out after 2% epinephrine. 57M experienced Contributing factors discussed.Fraunfelder 1978.Possible adverse effects from topical ocular 10% phenylephrine 0% not effect of subjects of subjects of subjects experiencing increased BP (69F, 3mth F, 62 M)Wilensky 1973Aryternesion following 10% phenylephrine ophthalmic. Acte Systemic Hypertension after conjunctival instillation and the drops 10% index of subjects of subjects experiencing increased BP (69F, 3mth F, 62 M)Wilensky 1973Ids of subscholnedieCase reports of subjects of subjects experiencing increased BP (69F, 3mth F, 62 M)Wilensky 1973Ids of subscholnedieCase reports BP went from 150/100 to 270/170 after proparacine one drop and three drops 10% index of subscholnedieMcReynolks 1956Hazards of use of sympathominetic drugs in ophthalmology and had subarachnoid benerofage in a 35 yo. A cotton wick soaked in 10% phenylephrine 10% interased in 2% (Criterion and had subarachnoid benerofage) N=60.Biggs 1959The effect of sympathominetic drugs upon the amplitude treated vith minister on indiven and separate posterior synechiae. BP went from 118/68 to 230/130 and a subscholnedie in the enonate.Biggs 1959The effect	Authors	Study title	a) Design
Yospiboon 2004Randomized Double-bind Study of Phenylephrine 2.5% vs. 10% on papillary dilatationPhenylephrine 2.9% (n=271). Both groups received 1% ropicamide. b) Phenylephrine 10% (n=273) vs phenylephrine 10% (n=273). So phenylephrine 10% (n=273). So phenylephrine 10% (n=273). So phenylephrine 10% (n=271). Both groups received 1% ropicamide. Si phenylephrine 10% (n=270). Both groups received 1% ropicamide. Si phenylephrine 10% (n=270). Both groups received 1% ropicamide. Si phenylephrine 10% (n=270). Both groups	Authors	Study title	a) Design b) Efficacy data
10% on papillary dilationb) Phenylephrine 10% more effective than 2.5% with significant difference between groups for the amount of additional dilation after topicamile 0-0.001 c) Significant difference on pulse rate p=0.005 but not SBP or DBP.Lansche RK 1966Systemic reactions to topical epinephrine and phenylephrine increased BP and HR and fainting after a single drop of 10% phenylephrine. 57M experienced 	Authors	Study title	a) Design b) Efficacy data c) Safety data
amount of addition after tropicande p-0.001 (> Significant difference on pulse rate p=0.005 but ot SBP or DBP.Lamsche RK 1966Systemic reactions to topical epinephrine and phenylephrine (Case reports of 2 subjects 40F had a headacheand passed out after 2% epinephrine, 57M experienced increased BP and HR and fainting after a single drop of 10% phenylephrine . Contributing factors discussed.Fraunfelder 1978.Possible adverse effects from topical ocular 10% phenylephrine3 case reports of subjects of subjects experiencing increased BP (60F, 3mth F, 62 M)Solosky 1972Hypertension following 10% phenylephrine ophthalmic. of Phenylephrine Hydrochloride3 case reports of subjects of subjects experiencing increased BP (60F, 3mth F, 62 M)McReynolds 1956Acute Systemic Hypertension after conjunctival instillation 	Authors Yospaiboon 2004	Study title Randomized Double-blind Study of Phenylephrine 2.5% vs	a) Design b) Efficacy data c) Safety data a) Phenylephrine 2.5% (n=293) vs phenylephrine 10% (n=271). Both groups received 1% tropicamide.
Lamsche RK 1966Systemic reactions to topical epinephrine and phenylephrinCase reports of 2 subjects 40F had a headache and passed out after 29% epinephrine, 57M experienced phenylephrineFraunfelder 1978.Possble adverse effects fron topical ocular 10% phenylephrineSa case reports of subjects of subjects vepriencing increased BP (69F, 3mth F, 62 M)Solosky 1972Hypertension following 10% phenylephrine ophthalmic.3 case reports of subjects of subjects experiencing increased BP (69F, 3mth F, 62 M)Wilensky 1973Acute Systemic Hypertension after conjunctival instillation of Phenylephrine HydrochlorideCase report: BP went from 150/100 to 270/170 after proparacaine one drop and three drops 10% phenylephrineMcReynolds 1956Hazards of use of sympathomimetic drugs in ophthalmologCase report: BP went from 150/100 to 270/170 after proparacaine one drop and three drops 10% phenylephrine inserted in lower cul de sac to induce dilatation and separate posterior synechiae. BP went from 118/68 to 230/130 and had subarachinoi bleed.Heath 1939Use of phenylephrine hydrochloride (neo-synephrine Hydrockloride) in ophthalmologyPhenylephrine inserted in a0%, lowered in slightly in about 58% and slightly increased in 2% (Criterion was ± 4mm Hg was no change) N=60.Biggs 1959The effect of phenylephrine hydrochloride on the motit treated eye.In ormal subjects phenylephrine 10% produced mydniss and thal inter on effect on the IOP of cyes treated with midscins. In subjects with the clinician might employ of refraction purposes.Becker 1959The effect of phenylephrine hydrochloride on the motit treated eye.a) Doublemasked comparison of phenylephrine 10% (n=3) and phenylephrine 2.5% (n=4) in low birth weight infraats	Authors Yospaiboon 2004	Study title Randomized Double-blind Study of Phenylephrine 2.5% vs 10% on papillary dilatation	a) Design b) Efficacy data c) Safety data a) Phenylephrine 2.5% (n=293) vs phenylephrine 10% (n=271). Both groups received 1% tropicamide. b) Phenylephrine 10% more effective than 2.5% with significant difference between groups for the
Lansche RK 1966Systemic reactions to topical epinephrine and phenylephrineCase reports 07 subjects 40F had a hachache and passed out after 2% epinephrine, 57M experienced increased BP and HR and finiting after a single drop of 10% phenylephrine. Contributing factors discussed.Framfelder 1978.Possible adverse effects from topical ocular 10% phenylephrine3 case reports of subjects of subjects experiencing increased BP (69F, 3mth F, 62 M)Solosky 1972Mypertension following 10% phenylephrine ophthalmic.3 case reports BP went from 150/100 to 270/170 after proparaciane one drop and three drops 10% phenylephrine Hydrochloride (neo-synephrine)McReynolds 1956Hazards of use of sympathonimetic drugs in ophthalmologyCaster eports BP went from 150/100 to 270/170 after proparaciane one drop and three drops 10% phenylephrine in a 55 yo. Acton wick soaked in 10% phenylephrine inserted in lower cul de sac to induce dialation and separate posterior synechiae. BP went from 118/68 to 230/130Heath 1939Use of phenylephrine hydrochloride (neo-synephrine) Hydrochloride) in ophthalmologyReported BP unaltered in 40%, lowered in slightly in about 58% and slightly increased in 2% (Criterion was ± tarmal fly ans no change) N=60.Biggs 1959The effect of sympathonimetic drugs upon the amplitude econnmodationPhenylephrine 10% entresively caused only a slight recession of the near point. No effect star ± tarmal flet with miorisc. In subjects thenylephrine 10% entresively caused only a slight recession of the near point. No effect star ± tarmal flet with miorisc. In subjects thenylephrine 10% (ner=3) and phenylephrine 2.5% (n=4) in low birth weight infinits.Biggs 1959The effect of phenylephrine hydrochloride on the miotic treated vec.In normal subjec	Authors Yospaiboon 2004	Study title Randomized Double-blind Study of Phenylephrine 2.5% vs 10% on papillary dilatation	a) Design b) Efficacy data c) Safety data a) Phenylephrine 2.5% (n=293) vs phenylephrine 10% (n=271). Both groups received 1% tropicamide. b) Phenylephrine 10% more effective than 2.5% with significant difference between groups for the amount of additional dilatation after tropicamide p<0.001
Increased BP and HR and fainting after a single drop of 10% phenylephrine . Contributing factors discussed.Frankfelder 1978.Possible adverse effects from topical ocular 10% phenylephrine3 case reports of subjects of subjects experiencing increased BP (69F, 3mth F, 62 M)Solosky 1972Hypertension following 10% phenylephrine ophthalmic.3 case reports of subjects of subjects experiencing increased BP (69F, 3mth F, 62 M)Wilensky 1973Acute Systemic Hypertension after conjunctial instillation of Phenylephrine Hydrochloride (neo-synephrine) phenylephrine at the drop of 10% phenylephrine inserted in nower culd eas to induce dilatation and separate posterior synechiae. BP went from 118/68 to 230/130McReynolds 1956Lyse of phenylephrine hydrochloride (neo-synephrine) Heath 1939Reported BP maltered in 40%, lowered in slightly in about 58% and slightly increased in 2% (Criterion was ± 4mm Hg was no change) N=60.Bigs 1959The effect of sympathonimetic drugs upon the amplitude upd columnodities. In subjects which the clinicani might employ for refraction purposes.Becker 1959The effect of phenylephrine hydrochloride on the mistic treated eye.In normal subjects phenylephrine 10% produced mydriasis and hali tille or no effect on the IOP of cyes treated eye.Borromeo-McGrail 1973Systemic hypertension following ocular administration of the enonate.Alobust-masked comparison of phenylephrine 10% (n=3) and phenylephrine 2.5% (n=4) in low birth weight infants.Borromeo-McGrail 1973Comparative study of mydriatic and cycloplegic agents in the enonate.No efficacy data cy (With phenylephrine 10% SBP up 12-16mmHg DBP up 10-14mmHg. Phenylephrine 2.5% (n=4) in low birth weight infants.Boro	Authors Yospaiboon 2004	Study title Randomized Double-blind Study of Phenylephrine 2.5% vs 10% on papillary dilatation	 a) Design b) Efficacy data c) Safety data a) Phenylephrine 2.5% (n=293) vs phenylephrine 10% (n=271). Both groups received 1% tropicamide. b) Phenylephrine 10% more effective than 2.5% with significant difference between groups for the amount of additional dilatation after tropicamide p=0.001 c) Significant difference on pulse rate p=0.005 but not SBP or DBP.
InterfactorContributing factors discussed.Francfelder 1978.PosebylephrimeSolowy topper factors motopical ocular 10%Interfactors discussed.Solowy 1972Hypertension following 10% phenylephrine ophthalmic.3 case reports of subjects of subjects experiencing increased BP (69F, 3mH F, 62 M)Wilensky 1973Acute Systemic Hypertension after conjunctival instillationCase reports BP went from 150/100 to 270/17 after proparacian one drop and three drops 10%McReynolds 1956Hzards of use of sympathomimetic drugs in ophthalmologyCase reports BP went from 150/100 to 270/170 after proparacian one drop and three drops 10%Biggs 1959Use of phenylephrine hydrochloride (neo-synephrineReported BP multered in 40%, lowered in slightly in about 58% and slightly increased in 2% (Criterion was ±4 mm Hg was no change) N=60.Biggs 1959The effect of spmpathomimetic drugs upon the amplitudePhenylephrine 10% administered intensively caused only a slight recession of the near point. No effect save and edge.Biecker 1959The effect of phenylephrine hydrochloride on the mionic treated eve.In normal subjects phenylephrine 10% produced mydraiss and hal tilte or no effect on the IOP of cyse caused a very slight increase in IOP.Bortomeo-McGrail 1073Systemic hypertension following ocular administration of treated vitin mionics.No comparative study of mydriatic and cycloplegic agents of the phenylephrine 10% sheaded single mydrais in blue brown and black cyss. Although numerically b) No efficacy data c) With phenylephrine 10% Sheade single mydrais in blue krees.Notes fact were single wise in black cyss.Burtomeo-McGrail 1974Acomparative study of mydriatic and cycloplegic agents	Authors Yospaiboon 2004 Lansche RK 1966	Study title Randomized Double-blind Study of Phenylephrine 2.5% vs 10% on papillary dilatation Systemic reactions to topical epinephrine and phenylephrine	a) Design b) Efficacy data c) Safety data a) Phenylephrine 2.5% (n=293) vs phenylephrine 10% (n=271). Both groups received 1% tropicamide. b) Phenylephrine 10% more effective than 2.5% with significant difference between groups for the amount of additional dilatation after tropicamide p=0.001 c) Significant difference on pulse rate p=0.005 but not SBP or DBP. Case reports of 2 subjects 40F had a headache and passed out after 2% epinephrine, 57M experienced
Francfeder 1978.Dessible particulation topical occular 10%International control of particulation topical occular 10%Solosky 1972Myertension following 10% phenylephrine ophthalmic.3 case reports of subjects of subjects or grantseade IP (6F, 3mth F, 62 M)Wilensky 1973Arche Systemic Hypertension after conjunctival instillationCase report: BP went from 150/100 to 270/170 after proparation one drop and three drops 10%McReynolds 1956Bazards of use of sympathonimetic drugs in ophthalmologyCase report: BP went from 150/100 to 270/170 after proparation one drop and three drops 10%Biggs 1959Use of polneylephrine hydrochloride (neo-synephrine)Reported Her maltered in 40%, howered in slightly in about 58% and slightly increased in 2% (Criterion on Control of Control or Grantset 10%)Biggs 1959Des effect of phenylephrine hydrochloride on the minitionIn normal subjects benylephrine 10% endumistered intensively caused only a slight recession of the nery optical on 2% phenylephrine 10% administered intensively caused only a slight recession of the nery optical on 25% phenylephrine 10% endumistered intensively caused only a slight recession of the nery optical on 25% phenylephrine 10% endumistered intensively caused only a slight recession of the nery optical on 25% phenylephrine 10% endumistered intensively caused only a slight recession of the nery optical on 25% phenylephrine 10% endumistered intensively caused only a slight recession of the nery optical on 25% phenylephrine 10% endumistered intensively caused only a slight recession of the nery optical on 25% phenylephrine 10% enduced set in 10% p	Authors Yospaiboon 2004 Lansche RK 1966	Study title Randomized Double-blind Study of Phenylephrine 2.5% vs 10% on papillary dilatation Systemic reactions to topical epinephrine and phenylephrine	a) Design b) Efficacy data c) Safety data a) Phenylephrine 2.5% (n=293) vs phenylephrine 10% (n=271). Both groups received 1% tropicamide. b) Phenylephrine 10% more effective than 2.5% with significant difference between groups for the amount of additional dilatation after tropicamide p=0.001 c) Significant difference on pulse rate p=0.005 but not SBP or DBP. Case reports of 2 subjects 40F had a headache and passed out after 2% epinephrine, 57M experienced increased BP and HR and fainting after a single drop of 10% phenylephrine .
Solosky 1972Hypertension following 10% phenylephrine ophthalmic.3 case reports of subjects of subjects experiencing increased BP (69F, 3mth F, 62 M)Wilensky 1973Acute Systemic Hypertension after conjunctival instillation of Phenylephrine HydrochlorideCase reports BP went from 150/100 to 270/170 after proparacaine one drop and three drops 10% phenylephrineMcReynolds 1956Hazards of use of sympathomimetic drugs in ophthalmologyAcute subarachnoid hemorrhage in a 35 yo. A cotton wick soaked in 10% phenylephrine inserted in induce dilatation and separate posterior synechias. BP went from 118/68 to 230/1300 and had subarachnoid bleed.Heath 1939Use of phenylephrine hydrochloride (neo-synephrine Hydrochloride) in ophthalmologyReported BP unaltered in 40%, lowered in slightly in about 58% and slightly increased in 2% (Criterion was noted at dosage levels which the clinician might employ for refraction purposes.Biggs 1959The effect of sympathomimetic drugs upon the amplitude of treated eye.Phenylephrine 10% administered intensively caused only a slight recession of the near point. No effect was noted at dosage levels which the clinician might employ for refraction purposes.Becker 1959The effect of phenylephrine hydrochloride on the miotic treated eye.In normal subjects phenylephrine 10% fonducen on demerarium bromide 0.25% phenylephrine 10% sansked comparison of phenylephrine 10% administer and 10% in objects with glaucom an demerarium bromide 0.25% phenylephrine 10% sansked comparison of phenylephrine 10% fonducen and there 4 eye.Borromeo-McGrail 1973Systemic hypertension following ocular administration of 10% phenylephrine 10% showed similar mydriasis in blue brown and black eyes. Although numerically the eright infants. b) No e	Authors Yospaiboon 2004 Lansche RK 1966	Study title Randomized Double-blind Study of Phenylephrine 2.5% vs 10% on papillary dilatation Systemic reactions to topical epinephrine and phenylephrine	a) Design b) Efficacy data c) Safety data c) Safety data a) Phenylephrine 2.5% (n=293) vs phenylephrine 10% (n=271). Both groups received 1% tropicamide. b) Phenylephrine 10% more effective than 2.5% with significant difference between groups for the amount of additional dilatation after tropicamide p=0.001 c) Significant difference on pulse rate p=0.005 but not SBP or DBP. Case reports of 2 subjects 40F had a headache and passed out after 2% epinephrine, 57M experienced increased BP and HR and fainting after a single drop of 10% phenylephrine . Contributing factors discussed.
Wilensky 1973 Acute Systemic Hypertension after conjunctival instillation of Phenylephrine Hydrochloride Case report: BP went from 150/100 to 270/170 after proparacine one drop and three drops 10% phenylephrine McReynolds 1956 Hazards of use of sympathomimetic drugs in ophthalmology Acute subarachnoid hemorrhage in a 35 yo. A cotton wick soaked in 10% phenylephrine inserted in jour cul de sac to induce dilatation and separate posterior synechiae. BP went from 118/68 to 230/130 and had subarachnoid bleed. Heath 1939 Use of phenylephrine hydrochloride (neo-synephrine Hydrochloride) in ophthalmology Reported BP unaltered in 40%, lowered in slightly in about \$8% and slightly increased in 2% (Criterion was ± 4mm Hg was no change) N=60. Biggs 1959 The effect of sympathomimetic drugs upon the amplitude of reacted with miotics. In subjects with alguects thenylephrine 10% administered intensively caused only a slight recession of the near point. No effect was noted at dosage levels which the clinician might employ for refraction purposes. Becker 1959 The effect of phenylephrine hydrochloride on the miotic treated eye. In normal subjects with alguecoma on demercarium bromide 0.25% phenylephrine 10% and was noted at dosage levels which the clinician might employ for refraction purposes. Borromeo-McGrail 1973 Systemic hypertension following ocular administration of 10% phenylephrine in the neonate. a) Double-masked comparison of phenylephrine 10% (n=3) and phenylephrine 2.5% (n=4) in low birth weight infants. Barbee 1957 A comparative study of mydriatic and cycloplegic agents in numan sub	Authors Yospaiboon 2004 Lansche RK 1966 Fraunfelder 1978.	Study title Randomized Double-blind Study of Phenylephrine 2.5% vs 10% on papillary dilatation Systemic reactions to topical epinephrine and phenylephrine Possible adverse effects from topical ocular 10% phenylephrine	a) Design b) Efficacy data c) Safety data a) Phenylephrine 2.5% (n=293) vs phenylephrine 10% (n=271). Both groups received 1% tropicamide. b) Phenylephrine 10% more effective than 2.5% with significant difference between groups for the amount of additional dilatation after tropicamide p=0.001 c) Significant difference on pulse rate p=0.005 but not SBP or DBP. Case reports of 2 subjects 40F had a headache and passed out after 2% epinephrine, 57M experienced increased BP and IR and faining after a single drop of 10% phenylephrine. Contributing factors discussed.
Winding 1973 Product synchrine Tryperitersion and conjunctival institution Case report. Synchrine Tryperitersion McReynolds 1956 Hazards of use of sympathomimetic drugs in ophthalmology Acute subarachnoid hemorrhage in a 35 yo. A cotton wick soaked in 10% phenylephrine inserted in lower cut de sa to induce dilation and separate posterior synechiae. BP went from 118/68 to 230/130 and had subarachnoid bleed. Heath 1939 Use of phenylephrine hydrochloride (neo-synephrine Hydrochloride) in ophthalmology Reported BP unaltered in 40%, lowered in slightly in about 58% and slightly increased in 2% (Criterion was ± 4mm Hg was no change) N=-60. Biggs 1959 The effect of sympathomimetic drugs upon the amplitude of recommodation Phenylephrine 10% administered intensively caused only a slight recession of the near point. No effect was ± 4mm Hg was no change) N=-60. Becker 1959 The effect of phenylephrine hydrochloride on the motio: treated eye. In normal subjects phenylephrine 10% produced mydriasis and had little or no effect on the IOP of eyes treated with minoris. In subjects with glaucoma on demercarium bromide 0.25% phenylephrine 10% caused a very slight increase in IOP. Borromeo-McGrail 1973 Systemic hypertension following ocular administration of 10% phenylephrine in the neonate. a) Double -masked comparison of phenylephrine 10% (n=3) and phenylephrine 2.5% (n=4) in low birth weight infinits. Barbee 1957 A comparative study of mydriatic and cycloplegic agents in norma- subjects without cye disease. Niffer phenylephrine produced similar mydriasis in bl	Authors Yospaiboon 2004 Lansche RK 1966 Fraunfelder 1978. Solosky 1972	Study title Randomized Double-blind Study of Phenylephrine 2.5% vs 10% on papillary dilatation Systemic reactions to topical epinephrine and phenylephrine Possible adverse effects from topical ocular 10% phenylephrine Hypertension following 10% phenylephrine cohthalmic.	 a) Design b) Efficacy data c) Safety data a) Phenylephrine 2.5% (n=293) vs phenylephrine 10% (n=271). Both groups received 1% tropicamide. b) Phenylephrine 10% more effective than 2.5% with significant difference between groups for the amount of additional dilatation after tropicamide p<0.001 c) Significant difference on pulse rate p=0.005 but not SBP or DBP. Case reports of 2 subjects 40F had a headache and passed out after 2% epinephrine, 57M experienced increased BP and HR and fainting after a single drop of 10% phenylephrine . Contributing factors discussed. 3 case reports of subjects of subjects experiencing increased BP (69F, 3mth F, 62 M)
McReynolds 1956 Hazards of use of sympathomimetic drugs in ophthalmology Accute subarchnoid hemorrhage in a 35 yo. A comparate posterior synechiae. BP went from 118/68 to 230/130 and had subarchnoid bleed. Heath 1939 Use of phenylephrine hydrochloride (nco-synephrine Hydrochloride) in ophthalmology Reported BP unaltered in 40%, lowered in slightly in about 58% and slightly increased in 2% (Criterion was ± 4mm Hg was no change) N=60. Biggs 1959 The effect of sympathomimetic drugs upon the amplitude of treated eye. In normal subjects phenylephrine 10% administered intensively caused only a slight recession of the near point. No effect was noted at dosage levels which the clinician might employ for refraction purposes. Bieges 1959 The effect of spenylephrine hydrochloride on the motiot: treated eye. In normal subjects phenylephrine 10% administered intensively caused only a slight recession of the near point. No effect was noted at dosage levels which the clinician might employ for refraction purposes. Borromeo-McGrail 1973 Systemic hypertension following occular administration of 10% phenylephrine 10% showed at mydrasis on of phenylephrine 10% (n=3) and phenylephrine 2.5% (n=4) in low birth weight infants. 0 No efficacy dat c) With phenylephrine 10% SBP up 12-16mmHg DBP up 10-14mmHg . Phenylephrine 2.5% had no effect Barbee 1957 Acomparative study of mydriatic and cycloplegic agents in normas subjects with gluey sizes. Review of the safety issues. Review of the safety issues.	Authors Yospaiboon 2004 Lansche RK 1966 Fraunfelder 1978. Solosky 1972	Study title Randomized Double-blind Study of Phenylephrine 2.5% vs 10% on papillary dilatation Systemic reactions to topical epinephrine and phenylephrine Possible adverse effects from topical ocular 10% phenylephrine Hypertension following 10% phenylephrine ophthalmic.	a) Design b) Efficacy data c) Safety data a) Phenylephrine 2.5% (m=293) vs phenylephrine 10% (m=271). Both groups received 1% tropicamide. b) Phenylephrine 10% more effective than 2.5% with significant difference between groups for the amount of additional dilatation after tropicamide p=0.001 c) Significant difference on pulse rate p=0.005 but not SBP or DBP. Case reports of 2 subjects 40F had a headache and passed out after 2% epinephrine, 57M experienced increased BP and HR and fainting after a single drop of 10% phenylephrine. Contributing factors discussed. 3 case reports of subjects of subjects experiencing increased BP (69F, 3mth F, 62 M) Comment DBment form 1000 (00 to 220120 of parameteriation and data advance 10%)
Intention Intention Intention Intention Heath 1939 Use of phenylephrine hydrochloride (neo-synephrine Hydrochloride) in ophthalmology schup Reported BP unaltered in 40%, lowered in slightly in about 58% and slightly increased in 2% (Criterion was a term Hg was no change) N=60. Biggs 1959 The effect of sympathonimetic drugs upon the amplitude of ecommodation Phenylephrine 10% administered intensively caused only a slight recession of the near point. No effect was noted at dosage levels which the clinician might employ for refraction purposes. Becker 1959 The effect of phenylephrine hydrochloride on the miobic trated eye. In normal subjects benylephrine 10% produced mydraiss and had little or no effect on the IOP of eyes caused a very slight increase in IOP. Borromeo-McGrail 1973 Systemic hygretension following ocular administration of 0% phenylephrine in the neonate. a) Doublemasked comparison of phenylephrine 10% (n=3) and phenylephrine 2.5% (n=4) in low birth vegita infants. b) No efficacy data c) With phenylephrine 10% show and black eyes. Although numerically the refreet O) With phenylephrine produced similar mydriasis in blue brown and black eyes. Although numerically mydraisis was less in black eyes. Matha Meyer 1980 Phenylephrine hydrochloride in Pharmacology of Ocular mos Review of the safety issues.	Authors Yospaiboon 2004 Lansche RK 1966 Fraunfelder 1978. Solosky 1972 Wilensky 1973	Study title Randomized Double-blind Study of Phenylephrine 2.5% vs 10% on papillary dilatation Systemic reactions to topical epinephrine and phenylephrine Possible adverse effects from topical ocular 10% phenylephrine Hypertension following 10% phenylephrine ophthalmic. Acute Systemic Hypertension after conjunctival instillation of Phenylephrine Hydrochloride	a) Design b) Efficacy data c) Safety data c) Safety data a) Phenylephrine 2.5% (n=293) vs phenylephrine 10% (n=271). Both groups received 1% tropicamide. b) Phenylephrine 10% more effective than 2.5% with significant difference between groups for the amount of additional dilatation after tropicamide p<0.001 c) Significant difference on pulse rate p=0.005 but not SBP or DBP. Case reports of 2 subjects 40F had a headache and passed out after 2% epinephrine, 57M experienced increased BP and HR and fainting after a single drop of 10% phenylephrine . Contributing factors discussed. 3 case reports of subjects of subjects experiencing increased BP (69F, 3mth F, 62 M) Case report: BP went from 150/100 to 270/170 after proparaciane one drop and three drops 10% phenylephrine
Heath 1939Use of phenylephrine hydrochloride (noe-synephrine Hydrochloride) in ophthalmologyReported BP multered in 40%, lowered in slightly in about \$8% and slightly increased in 2% (Criterion was ± 4mm Hg was no change) N=60.Biggs 1959The effect of sympathomimetic drugs upon the amplitude of commodationPhenylephrine 10% administered intensively caused only a slight recession of the near point. No effect was no change) N=60.Becker 1959The effect of phenylephrine hydrochloride on the miniot: treated eye.In normal subjects phenylephrine 10% administered intensively caused only a slight recession of the near point. No effect of sympathomimetic drugs upon the amplitude of treated vith miniots.In normal subjects with gladuced mydriasis and hal tittle or no effect on the IOP of eyes caused a very slight increase in IOP.Borromeo-McGrail 1973Systemic hydrochloridg coular administration of hydrophenylephrine 10% schedat a cylight infrass.a) Double-masked comparison of phenylephrine 10% (n=3) and phenylephrine 2.5% (n=4) in low birth weight infrass.Barbee 1957A comparative study of mydriatic and cycloplegic agents in human subjects with glotycely since of since agent of since agent in 10% phenylephrine 10% scheda (since agent in 10% phenylephrine 2.5% (n=4) in low birth weight infranss.Barbee 1957A comparative study of mydriatic and cycloplegic agent in since agent in 10% phenylephrine 10% scheda (since agent in 10% phenylephrine 10% scheda (since agent in 10% phenylephrine hydrochloride in Pharmacology of Ocula	Authors Yospaiboon 2004 Lansche RK 1966 Fraunfelder 1978. Solosky 1972 Wilensky 1973 McReynolds 1956	Study title Randomized Double-blind Study of Phenylephrine 2.5% vs 10% on papillary dilatation Systemic reactions to topical epinephrine and phenylephrine Possible adverse effects from topical ocular 10% phenylephrine Hypertension following 10% phenylephrine ophthalmic. Acute Systemic Hypertension after conjunctival instillation of Phenylephrine Hydrochloride Hazards of use of sympathomimetic drugs in ophthalmology	a) Design b) Efficacy data c) Safety data c) Safety data a) Phenylephrine 2.5% (n=293) vs phenylephrine 10% (n=271). Both groups received 1% tropicamide. b) Phenylephrine 10% more effective than 2.5% with significant difference between groups for the amount of additional dilatation after tropicamide p=0.001 c) Significant difference on pulse rate p=0.005 but not SBP or DBP. Case reports of 2 subjects 40F had a headache and passed out after 2% epinephrine. 57M experienced increased BP and IR and fainting after a single drop of 10% phenylephrine . Contributing factors discussed. 3 case reports of subjects of subjects experiencing increased BP (69F, 3mth F, 62 M) Case reports BP went from 150/100 to 270/170 after proparacine one drop and three drops 10% phenylephrine Acute subarachnoid hemorrhage in a 35 yo. A cotton wick soaked in 10% phenylephrine inserted in low device dilatation and separate posterior synechiae. BP went from 118/68 to 230/130
Biggs 1959 The effect of sympathonimetic drugs upon the amplitude of accommodation Phenylephrine 10% administered intensively caused only a slight recession of the near point. No effect was noted at dosage levels which the clinician might employ for refraction purposes. Becker 1959 The effect of phenylephrine hydrochloride on the mioinc treated eye. In normal subjects phenylephrine 10% produced mydriasis and had little or no effect on the IOP of eyes treated with mioins. In subjects with glaucoma on demercarium bromide 0.25% phenylephrine 10% caused a very slight increase in IOP. Borromeo-McGrail 1973 Systemic hypertension following ocular administration of 10% phenylephrine in the neonate. a) Double-masked comparison of phenylephrine 10% (n=3) and phenylephrine 2.5% (n=4) in low birth very slight increase in IOP. Barbee 1957 A comparative study of mydriatic and cycloplegic agents in human subjects without eye disease. IO% phenylephrine produced similar mydriasis in blue brown and black eyes. Although numerically the mydriasis was less in black eyes. Mattha Meyer 1980 Phenylephrine hydrochloride in Pharmacology of Ocular mos Review of the safety issues.	Authors Yospaiboon 2004 Lansche RK 1966 Fraunfelder 1978. Solosky 1972 Wilensky 1973 McReynolds 1956	Study title Randomized Double-blind Study of Phenylephrine 2.5% vs 10% on papillary dilatation Systemic reactions to topical epinephrine and phenylephrine Possible adverse effects from topical ocular 10% phenylephrine Hypertension following 10% phenylephrine ophthalmic. Acute Systemic Hypertension after conjunctival instillation of Phenylephrine Hydrochloride Hazards of use of sympathomimetic drugs in ophthalmology	a) Design b) Efficacy data c) Safety data c) Safety data c) Safety data a) Phenylephrine 2.5% (m=293) vs phenylephrine 10% (m=271). Both groups received 1% tropicamide. b) Phenylephrine 10% more effective than 2.5% with significant difference between groups for the anount of additional dilatation after tropicamide p=0.001 c) Significant difference on pulse rate p=0.005 but not SBP or DBP. Case reports of 2 subjects 40F had a headache and passed out after 2% epinephrine, 57M experienced increased BP and HR and fainting after a single drop of 10% phenylephrine . Contributing factors discussed. 3 case reports of subjects of subjects experiencing increased BP (69F, 3mth F, 62 M) Case report: BP went from 150/100 to 270/170 after proparaciane one drop and three drops 10% phenylephrine Acute subarachnoid hemorrhage in a 35 yo. A cotton wick soaked in 10% phenylephrine inserted in lower cul de as to induce dilatation and separate posterior synechiae. BP went from 118/68 to 230/130 and had subarachnoid bleed.
Becker 1959 The effect of phenylephrine hydrochloride on the motici treated eye. In normal subjects phenylephrine 10% produced mydriasis and had little or no effect on the IOP of eyes treated with motics. In subjects with glaucoma on demercarium bromide 0.25% phenylephrine 10% caused a very slight increase in IOP. Borromeo-McGrail 1973 Systemic hypertension following ocular administration of 10% phenylephrine in the neonate. a) Doublemasked comparison of phenylephrine 10% (n=3) and phenylephrine 2.5% (n=4) in low birth weight infants. Borromeo-McGrail 1973 A comparative study of mydriatic and cycloplegic agents in human subjects without eye disease. 10% phenylephrine produced similar mydriasis in blue brown and black eyes. Although numerically the mydriasis was less in black eyes. Mattha Meyer 1980 Phenylephrine hydrochloride in Pharmacology of Ocular Dows Review of the safety issues.	Authors Yospaiboon 2004 Lansche RK 1966 Fraunfelder 1978. Solosky 1972 Wilensky 1973 McReynolds 1956 Heath 1939	Study title Randomized Double-blind Study of Phenylephrine 2.5% vs 10% on papillary dilatation Systemic reactions to topical epinephrine and phenylephrine Possible adverse effects from topical ocular 10% phenylephrine Hypertension following 10% phenylephrine ophthalmic. Acute Systemic Hypertension after conjunctival instillation of Phenylephrine Hydrochloride Hazards of use of sympathomimetic drugs in ophthalmology Use of phenylephrine hydrochloride (neo-synephrine Hydrochloride) in ophthalmology	a) Design b) Efficacy data c) Safety data c) Safety data a) Phenylephrine 2.5% (n=293) vs phenylephrine 10% (n=271). Both groups received 1% tropicamide. b) Phenylephrine 10% more effective than 2.5% with significant difference between groups for the amount of additional dilatation after tropicamide p=0.001 c) Significant difference on pulse rate p=0.005 but not SBP or DBP. Case reports of 2 subjects 40F had a headache and passed out after 2% epinephrine, 57M experienced increased BP and HR and fainting after a single drop of 10% phenylephrine. Contributing factors discussed. 3 case reports of subjects of subjects experiencing increased BP (69F, 3mth F, 62 M) Case report: BP went from 150/100 to 270/170 after proparacaine one drop and three drops 10% phenylephrine Acute subarachnoid hemorrhage in a 35 yo. A cotton wick soaked in 10% phenylephrine inserted in lower cul de sac to induce dilatation and separate posterior synechiae. BP went from 118/68 to 230/130 and had subarachnoid bleed. Reported BP unaltered in 40%, lowered in slightly in about 58% and slightly increased in 2% (Criterion
Instantial of the product of and system in the product of	Authors Yospaiboon 2004 Lansche RK 1966 Fraunfelder 1978. Solosky 1972 Wilensky 1973 McReynolds 1956 Heath 1939 Biggs 1959	Study title Randomized Double-blind Study of Phenylephrine 2.5% vs 10% on papillary dilatation Systemic reactions to topical epinephrine and phenylephrine Possible adverse effects from topical ocular 10% phenylephrine Hypertension following 10% phenylephrine ophthalmic. Acette Systemic Hypertension after conjunctival instillation of Phenylephrine Hydrochloride Hazards of use of sympathomimetic drugs in ophthalmology Use of phenylephrine hydrochloride (neo-synephrine Hydrochloride) in ophthalmology The effect of sympathomimetic drugs upon the amplitude of accommodation	 a) Design b) Efficacy data c) Safety data a) Phenylephrine 2.5% (m=293) vs phenylephrine 10% (m=271). Both groups received 1% tropicamide. b) Phenylephrine 10% more effective than 2.5% with significant difference between groups for the amount of additional dilatation after tropicamide p=0.001 c) Significant difference on pulse rate p=0.005 but not SBP or DBP. Case reports of 2 subjects 40F had a headache and passed out after 2% epinephrine, 57M experienced increased BP and HR and fainting after a single drop of 10% phenylephrine. Contributing factors discussed. 3 case reports of subjects of subjects experiencing increased BP (69F, 3mth F, 62 M) Case reports BP went from 150/100 to 270/170 after proparaciane one drop and three drops 10% phenylephrine Acute subarachnoid hemorrhage in a 35 yo. A cotton wick soaked in 10% phenylephrine inserted in lower cul de sac to induce dilatation and separate posterior syncchiae. BP went from 118/68 to 230/130 and had subarachnoid bleed. Reported BP unaltered in 40%, lowered in slightly in about 58% and slightly increased in 2% (Criterion ws ± 4mm Hg was no change) N=60. Phenylephrine 10% administered intensively caused only a slight recession of the near point. No effect was noted at dosage levels which the clinician might employ for refraction purposes.
Borromeo-McGrail 1973 Systemic hypertension following ocular administration of 10% phenylephrine in the neonate. a) Double - masked comparison of phenylephrine 10% (n=3) and phenylephrine 2.5% (n=4) in low birth weight infants. b) No efficacy data c) With phenylephrine 10% SBP up 12-16mmHg DBP up 10-14mmHg. Phenylephrine 2.5% had no effect Barbee 1957 A comparative study of mydriatic and cycloplegic agents in human subjects without eye disease. 10% phenylephrine produced similar mydriasis in blue brown and black eyes. Although numerically the mydriasis was less in black eyes. Martha Meyer 1980 Phenylephrine hydrochloride in Pharmacology of Ocular Dows Review of the safety issues.	Authors Yospaiboon 2004 Lansche RK 1966 Fraunfelder 1978. Solosky 1972 Wilensky 1973 McReynolds 1956 Heath 1939 Biggs 1959 Becker 1959	Study title Randomized Double-blind Study of Phenylephrine 2.5% vs 10% on papillary dilatation Systemic reactions to topical epinephrine and phenylephrine Possible adverse effects from topical ocular 10% phenylephrine Hypertension following 10% phenylephrine ophthalmic. Acute Systemic Hypertension after conjunctival instillation of Phenylephrine Hydrochloride Hazards of use of sympathomimetic drugs in ophthalmology Use of phenylephrine Hydrochloride (neo-synephrine Hydrochloride) in ophthalmology The effect of sympathomimetic drugs upon the amplitude of accommodation	 a) Design b) Efficacy data c) Safety data c) Safety data c) Safety data a) Phenylephrine 2.5% (m=293) vs phenylephrine 10% (m=271). Both groups received 1% tropicamide. b) Phenylephrine 10% more effective than 2.5% with significant difference between groups for the amount of additional dilatation after tropicamide p=0.001 c) significant difference on pulse rate p=0.005 but not SBP or DBP. Case reports of 2 subjects 40F had a headache and passed out after 2% epinephrine, 57M experienced increased BP and HR and faiting after a single drop of 10% phenylephrine . Contributing factors discussed. 3 case reports of subjects of subjects experiencing increased BP (69F, 3mth F, 62 M) Case reports of subjects of subjects experiencing increased BP (69F, 3mth F, 62 M) Case reports as to induce dilatation and separate posterior synechiae. BP went from 118/68 to 230/130 and had subarachnoid bleed. Reported BP unaltered in 40%, lowered in slightly in about 58% and slightly increased in 2% (Criterion was ± 4mm Hg was no change) N=60. Phenylephrine 10% administered intensively caused only a slight recession of the near point. No effect was noted at dosage levels which the clinician might employ for refraction purposes.
Image: Note of the state of the st	Authors Yospaiboon 2004 Lansche RK 1966 Fraunfelder 1978. Solosky 1972 Wilensky 1973 McReynolds 1956 Heath 1939 Biggs 1959 Becker 1959	Study title Randomized Double-blind Study of Phenylephrine 2.5% vs 10% on papillary dilatation Systemic reactions to topical epinephrine and phenylephrine Possible adverse effects from topical ocular 10% phenylephrine Hypertension following 10% phenylephrine ophthalmic. Acette Systemic Hypertension after conjunctival instillation of Phenylephrine Hydrochloride Hazards of use of sympathomimetic drugs in ophthalmology Use of phenylephrine hydrochloride (neo-synephrine Hydrochloride) in ophthalmology The effect of sympathomimetic drugs upon the amplitude of accommodation The effect of phenylephrine hydrochloride on the miotic treated cye.	 a) Design b) Efficacy data c) Safety data a) Phenylephrine 2.5% (m=293) vs phenylephrine 10% (m=271). Both groups received 1% tropicamide. b) Phenylephrine 10% more effective than 2.5% with significant difference between groups for the amount of additional dilatation after tropicamide p=0.001 c) Significant difference on pulse rate p=0.005 but not SBP or DBP. Case reports of 2 subjects 40F had a headache and passed out after 2% epinephrine, 57M experienced increased BP and HR and fainting after a single drop of 10% phenylephrine . Contributing factors discussed. 3 case reports of subjects of subjects experiencing increased BP (69F, 3mth F, 62 M) Case report: BP went from 150/100 to 270/170 after proparacaine one drop and three drops 10% phenylephrine Actute subarachnoid hemorrhage in a 35 yo. A cotton wick soaked in 10% phenylephrine inserted in lower cul de sact to induce dilatation and separate posterior synechiae. BP went from 118/68 to 230/130 and had subarachnoid bleed. Reported BP unaltered in 40%, lowered in slightly in about 58% and slightly increased in 2% (Criterion was 1 daministered intensively caused only a slight recession of the near point. No effect was noted at dosage levels which the cliniciam might employ for refraction purposes. In normal subjects phenylephrine 10% produced mydriasis and had little or no effect on the IOP of eyes treated with mitorics. In 20% criterion in Q2% (phenylephrine 10% caused on phenylephrine 10%
b) No efficacy data c) With phenylephrine 10% SBP up 12-16mmHg DBP up 10-14mmHg . Phenylephrine 2.5% had no effect Barbee 1957 A comparative study of mydriatic and cycloplegic agents in human subjects without eye disease. 10% phenylephrine produced similar mydriasis in blue brown and black eyes. Although numerically the mydriasis was less in black eyes. Martha Meyer 1980 Phenylephrine hydrochloride in Pharmacology of Ocular Duros Review of the safety issues.	Authors Yospaiboon 2004 Lansche RK 1966 Fraunfelder 1978. Solosky 1972 Wilensky 1973 McReynolds 1956 Heath 1939 Biggs 1959 Becker 1959 Borromeo-McGrail 1973	Study title Randomized Double-blind Study of Phenylephrine 2.5% vs 10% on papillary dilatation Systemic reactions to topical epinephrine and phenylephrine Possible adverse effects from topical ocular 10% phenylephrine Hypertension following 10% phenylephrine ophthalmic. Acute Systemic Hypertension after conjunctival instillation of Phenylephrine Hydrochloride Hazrds of use of sympathomimetic drugs in ophthalmology Use of phenylephrine hydrochloride (neo-synephrine Hydrochloride) in ophthalmology The effect of sympathomimetic drugs upon the amplitude of accommodation The effect of phenylephrine hydrochloride on the miotic treated eye. Systemic hypertension following ocular administration of	 a) Design b) Efficacy data c) Safety data c) Safety data c) Safety data a) Phenylephrine 10% more effective than 2.5% with significant difference between groups for the amount of additional dilatation after tropicamide p=0.001 c) significant difference on pulse rate p=0.005 but not SBP or DBP. Case reports of 2 subjects 40F had a headache and passed out after 2% epinephrine, 57M experienced increased BP and IR and fainting after a single drop of 10% phenylephrine . Contributing factors discussed. 3 case reports of subjects of subjects experiencing increased BP (69F, 3mth F, 62 M) Case reports of subjects of subjects experiencing increased BP (69F, 3mth F, 62 M) Case reports BP went from 150/100 to 270/170 after proparacaine one drop and three drops 10% phenylephrine inserted in lower cul de sac to induce dilatation and separate posterior synechiae. BP went from 118/68 to 230/130 and had subarachnoid bleed. Reported BP unalitered in 40%, lowered in slightly in about 58% and slightly increased in 2% (Criterion was ± 4mm Hg was no change) N=60. Phenylephrine 10% subjects with the clinician might employ for refraction purposes. In normal subjects phenylephrine 10% in the drop of yes treated with miotics. In subjects with glaucoma on demercarium bromide 0.25% phenylephrine 10% and a subarachoid blace.
Image: Constraint of the state of	Authors Yospaiboon 2004 Iansche RK 1966 Fraunfelder 1978. Solosky 1972 Wilensky 1973 McReynolds 1956 Heath 1939 Biggs 1959 Becker 1959 Borromeo-McGrail 1973	Study title Randomized Double-blind Study of Phenylephrine 2.5% vs 10% on papillary dilatation Systemic reactions to topical epinephrine and phenylephrine Possible adverse effects from topical ocular 10% phenylephrine Hypertension following 10% phenylephrine ophthalmic. Acute Systemic Hypertension after conjunctival instillation of Phenylephrine Hydrochloride Hazards of use of sympathomimetic drugs in ophthalmology The effect of sympathomimetic drugs upon the amplitude of accommodation The effect of sympathomimetic drugs upon the amplitude of accommodation The effect of phenylephrine hydrochloride on the miotic treated eye. Systemic hypertension following ocular administration of 10% phenylephrine in the neonate.	 a) Design b) Efficacy data c) Safety data a) Phenylephrine 2.5% (n=293) vs phenylephrine 10% (n=271). Both groups received 1% tropicamide. b) Phenylephrine 10% more effective than 2.5% with significant difference between groups for the amount of additional dilatation after tropicamide p<0.001 c) Significant difference on pulse rate p=0.005 but not SBP or DBP. Case reports of 2 subjects 40F had a headache and passed out after 2% epinephrine, 57M experienced increased BP and IR and faiting after a single drop of 10% phenylephrine . Contributing factors discussed. 3 case reports of subjects of subjects experiencing increased BP (69F, 3mth F, 62 M) Case reports of subjects of subjects experiencing increased BP (69F, 3mth F, 62 M) Case reports BP went from 150/100 to 270/170 after proparaciane one drop and three drops 10% phenylephrine Acute subarachnoid hemorrhage in a 35 yo. A cotton wick soaked in 10% phenylephrine inserted in lower cul de as to induce dilation and separate posterior synechiae. BP went from 118/68 to 230/130 and had subarachnoid bleed. Reported BP unaltered in 40%, lowered in slightly in about 58% and slightly increased in 2% (Criterion was ± 4mm Hg was no change) N=60. Phenylephrine 10% administered intensively caused only a slight recession of the near point. No effect was noted at dosage levels which the clinician might employ for refraction purposes. In normal subjects phenylephrine 10%. a) Double – masked comparison of phenylephrine 10% (n=3) and phenylephrine 2.5% (n=4) in low birth weight infants.
cffect Barbee 1957 A comparative study of mydriatic and cycloplegic agents in human subjects without eye disease. 10% phenylephrine produced similar mydriasis in blue brown and black eyes. Although numerically the mydriasis was less in black eyes. Martha Meyer 1980 Drues Phenylephrine hydrochloride in Pharmacology of Ocular Drues Review of the safety issues.	Authors Yospaiboon 2004 Lansche RK 1966 Fraunfelder 1978. Solosky 1972 Wilensky 1973 McReynolds 1956 Heath 1939 Biggs 1959 Becker 1939 Borromeo-McGrail 1973	Study title Randomized Double-blind Study of Phenylephrine 2.5% vs 10% on papillary dilatation Systemic reactions to topical epinephrine and phenylephrine Possible adverse effects from topical ocular 10% phenylephrine Hypertension following 10% phenylephrine ophthalmic. Acute Systemic Hypertension after conjunctival instillation of Phenylephrine Hydrochloride Hazards of use of sympathomimetic drugs in ophthalmology Use of phenylephrine hydrochloride (neo-synephrine Hydrochloride) in ophthalmology The effect of sympathomimetic drugs upon the amplitude of accommodation The effect of phenylephrine hydrochloride on the miotic treated eye. Systemic hypertension following ocular administration of 10% phenylephrine in the neonate.	 a) Design b) Efficacy data c) Safety data a) Phenylephrine 2.5% (m=293) vs phenylephrine 10% (m=271). Both groups received 1% tropicamide. b) Phenylephrine 10% more effective than 2.5% with significant difference between groups for the amount of additional dilatation after tropicamide p=0.001 c) Significant difference on pulse rate p=0.005 but not SBP or DBP. Case reports of 2 subjects 40F had a headache and passed out after 2% epinephrine, 57M experienced increased BP and IR and fainting after a single drop of 10% phenylephrine . Contributing factors discussed. 3 case reports of subjects of subjects experiencing increased BP (69F, 3mth F, 62 M) Case report: BP went from 150/100 to 270/170 after proparacaine one drop and three drops 10% phenylephrine inserted in lower cut dis to induce dilatation and separate posterior synechiae. BP went from 118/68 to 230/130 and had subarachnoid bleed. Reported BP unaltered in 40%, lowered in slightly in about 58% and slightly increased m 2% (Criterion was ± 4mm Hg was no change) N=60. Phenylephrine 10% administer di intensively caused only a slight recession of the near point. No effect treat of with notics. In subjects biervice time inside guardom on demecrarium bromide 0.25% phenylephrine 10% enasted at over y slight increase in IOP. a) Doublemasked comparison of phenylephrine 10% (n=3) and phenylephrine 2.5% (n=4) in low birth weight infants.
Barbee 1957 A comparative study of mydriatic and cycloplegic agents in human subjects without eye disease. 10% phenylephrine produced similar mydriasis in blue brown and black eyes. Although numerically the mydriasis was less in black eyes. Martha Meyer 1980 Drues Phenylephrine hydrochloride in Pharmacology of Ocular Drues Review of the safety issues.	Authors Yospaiboon 2004 Lansche RK 1966 Fraunfelder 1978. Solosky 1972 Wilensky 1973 McReynolds 1956 Heath 1939 Biggs 1959 Becker 1959 Borromeo-McGrail 1973	Study title Randomized Double-blind Study of Phenylephrine 2.5% vs 10% on papillary dilatation Systemic reactions to topical epinephrine and phenylephrine Possible adverse effects from topical ocular 10% phenylephrine Hypertension following 10% phenylephrine ophthalmic. Acute Systemic Hypertension after conjunctival instillation of Phenylephrine Hydrochloride Hazards of use of sympathomimetic drugs in ophthalmology Use of phenylephrine hydrochloride (neo-synephrine Hydrochloride) in ophthalmology The effect of sympathomimetic drugs upon the amplitude of accommodation The effect of phenylephrine hydrochloride on the miotic treated eye. Systemic hypertension following ocular administration of 10% phenylephrine in the neonate.	 a) Design b) Efficacy data c) Safety data c) Safety data c) Safety data a) Phenylephrine 10% more effective than 2.5% with significant difference between groups for the amount of additional dilatation after tropicamide p=0.001 c) Significant difference on pulse rate p=0.005 but not SBP or DBP. Case reports of 2 subjects 40F had a headache and passed out after 2% epinephrine, 57M experienced increased BP and IR and fainting after a single drop of 10% phenylephrine. Contributing factors discussed. 3 case reports of subjects of subjects experiencing increased BP (69F, 3mth F, 62 M) Case reports BP went from 150/100 to 270/170 after proparacaine one drop and three drops 10% phenylephrine inserted in lower cul de sac to induce dilatation and separate posterior synechiae. BP went from 118/68 to 230/130 and had subarachnoid bleed. Reported BP unaltered in 40%, lowered in slightly in about 58% and slightly increased in 2% (Criterion was ± 4mm Hg was no change) N=60. Phenylephrine 10% administered intensively caused only a slight recession of the near point. No effect was noted at dosage levels which the clinician might employ for refraction purposes. In normal subjects phenylephrine 10% placed mydrasis and had little or no effect on the IOP of eyes treated with miotics. In subjects with glaucoma on demercarium bromide 0.25% phenylephrine 10% caused a very slight increase in IOP. A) Doublemasked comparison of phenylephrine 10% (n=3) and phenylephrine 2.5% (n=4) in low birth weight infants. b) No efficacy data c) With phenylephrine 10% SBP up 12-16mmHg DBP up 10-14mmHg . Phenylephrine 2.5% had no
Martha Meyer 1980 Phenylephrine hydrochloride in Pharmacology of Ocular Review of the safety issues.	Authors Yospaiboon 2004 Lansche RK 1966 Fraunfelder 1978. Solosky 1972 Wilensky 1973 McReynolds 1956 Heath 1939 Biggs 1959 Becker 1959 Borromeo-McGrail 1973	Study title Randomized Double-blind Study of Phenylephrine 2.5% vs 10% on papillary dilatation Systemic reactions to topical epinephrine and phenylephrine Possible adverse effects from topical ocular 10% phenylephrac Hypertension following 10% phenylephrine ophthalmic. Acute Systemic Hypertension after conjunctival instillation of Phenylephrine Hydrochloride Hazards of use of sympathomimetic drugs in ophthalmology Use of phenylephrine hydrochloride (neo-synephrine Hydrochloride) in ophthalmology The effect of sympathomimetic drugs upon the amplitude of accommodation The effect of phenylephrine hydrochloride on the miotic treated cye. Systemic hypertension following ocular administration of 10% phenylephrine in the neonate.	 a) Design b) Efficacy data c) Safety data a) Phenylephrine 2.5% (n=293) vs phenylephrine 10% (n=271). Both groups received 1% tropicamide. b) Phenylephrine 10% more effective than 2.5% with significant difference between groups for the amount of additional dilatation after tropicamide p<0.001 c) Significant difference on pulse rate p=0.005 but not SBP or DBP. Case reports of 2 subjects 40F had a headache and passed out after 2% epinephrine, 57M experienced increased BP and HR and faiting after a single drop of 10% phenylephrine . Contributing factors discussed. 3 case reports of subjects of subjects experiencing increased BP (69F, 3mth F, 62 M) Case reports of subjects of subjects experiencing increased BP (69F, 3mth F, 62 M) Case reports and the and faition and separate posterior synechiae. BP went from 118/68 to 230/130 and had subarachnoid bleed. Reported BP unaltered in 40%, lowered in slightly in about 58% and slightly increased in 2% (Criterion was ± 4mm Hg was no change) N=06. Phenylephrine 10% administered intensively caused only a slight recession of the near point. No effect was noted at dosage levels which the clinician might employ for refraction purposes. In normal subjects phenylephrine 10% produced mydriasis and had hilter or no effect on the IOP of eyes treated with increase in IOP. a) Double-masked comparison of phenylephrine 10% (n=3) and phenylephrine 2.5% (n=4) in low birth weight infants. b) No efficacy data c) With phenylephrine 10% SBP up 12-16mmHg DBP up 10-14mmHg . Phenylephrine 2.5% had no effect
	Authors Yospaiboon 2004 Lamsche RK 1966 Fraunfelder 1978. Solosky 1972 Wilensky 1973 McReynolds 1956 Heath 1939 Biggs 1959 Becker 1959 Borromeo-McGrail 1973 Barbee 1957	Study title Randomized Double-blind Study of Phenylephrine 2.5% vs 10% on papillary dilatation Systemic reactions to topical epinephrine and phenylephrine Possible adverse effects from topical ocular 10% phenylephrine Hypertension following 10% phenylephrine ophthalmic. Acute Systemic Hypertension after conjunctival instillation of Phenylephrine Hydrochloride Hazrds of use of sympathomimetic drugs in ophthalmology Use of phenylephrine hydrochloride (neo-synephrine Hydrochloride) in ophthalmology The effect of sympathomimetic drugs upon the amplitude of accommodation The effect of phenylephrine hydrochloride on the miotic treated eye. Systemic hypertension following ocular administration of 10% phenylephrine in the neonate. A comparative study of mydriatic and cycloplegic agents in human subjects without eye disease.	 a) Design b) Efficacy data c) Safety data c) Safety data c) Safety data c) Phenylephrine 10% more effective than 2.5% with significant difference between groups for the amount of additional dilatation after tropicamide p=0.001 c) significant difference on pulse rate p=0.005 but not SBP or DBP. Case reports of 2 subjects 40F had a headache and passed out after 2% epinephrine, 57M experienced increased BP and IR and fainting after a single drop of 10% phenylephrine. Contributing factors discussed. 3 case reports of subjects of subjects experiencing increased BP (69F, 3mth F, 62 M) Case reports of subjects of subjects experiencing increased BP (69F, 3mth F, 62 M) Case report: BP went from 150/100 to 270/170 after proparacaine one drop and three drops 10% phenylephrine Acute subarachnoid hemorrhage in a 35 yo. A cotton wick soaked in 10% phenylephrine inserted in lower cul de sac to induce dilatation and separate posterior synechiae. BP went from 118/68 to 230/130 and had subarachnoid bleed. Reported BP unalitered in 40%, lowered in slightly in about 58% and slightly increased in 2% (Criterion was ± 4mm Hg was no change) N=60. Phenylephrine 10% solubiects with glaucoma on demecrarium bromide 0.25% phenylephrine 10% caused a very slight increase in IOP. A) Doublemasked comparison of phenylephrine 10% (n=3) and phenylephrine 2.5% (n=4) in low birth weight infants. b) No efficacy data (c) With phenylephrine 10% SBP up 12-16mmHg DBP up 10-14mmHg . Phenylephrine 2.5% had no effect OW the phenylephrine 10% SBP up 12-16mmHg DBP up 10-14mmHg . Although numerically the mydraisi was less in black eves.

Authors	Study title	a) Design b) Efficacy data c) Safety data
Pless 2003	Topical phenylephrine may result in worsening of visual loss when used to dilate pupils in patients with vaso- occlusive disease of the optic nerve.	Report on 4 patients with non-arteritic ischemic optic neuropathy who experienced acute worsening of visual function after phenylephrine used for fundus exam. 45 mins to 12 hrs later. All on 2.5% phenylephrine plus 0.5-1.0% tropicamide.
Alpay 2010	The local vasoconstriction of infant's skin following instillation of mydriatic eye drops.	Two case reports in neonates of extensive blanching of the skin after 2.5% phenylephrine Suggests reducing drop size and wiping away excess.
Lee 1958	The influence of epinephrine and phenylephrine on Intraocular Pressure.	Patients with OAG and normals IOP effect variable Studied phenylephrine 1% and 10%.
Sindel 1986	A comparison of the papillary and cardiovascular effects of various mydriatic agents in preterm infants.	a) Randomized. A. Phenylephrine 2.5% tropicamide 1.0% (n= 10) B. Phenylephrine 2.5% tropicamide 0.5% (n=10) C. phenylephrine 1.0% tropicamide 1.0% (n=10) D. Saline (n=4) b) Mydriasis in groups A and B was not different. Group C was less in bright light but still >6mm c) BP and HR changes significantly less in group C
Vaughan 1973	Ventricular arrhythmias after topical vasoconstrictors.	Case report of an 8 yo under GA for squint surgery. 4-5 drops 10% phenylephrine sent BP up 100/60 to 190/120 HB slowed. Multiple premature ventricular contractions.

7.1.2 Adequacy of Data

Reference literature reports, surveys, and articles cited in this review are representative of the published literature. They are adequate to make a determination of the safety of the 2.5% and 10% phenylephrine hydrochloride concentrations. There is no evidence that these references refer to trials not conducted in accordance with acceptable clinical ethical standards.

7.1.3 Pooling Data Across Studies to Estimate and Compare Incidence

Pooling of data across various studies was not informative given the variety of studies performed, i.e. case report studies, non- randomized studies, randomized studies, etc.

7.2 Adequacy of Safety Assessments

7.2.1 Overall Exposure at Appropriate Doses/Durations and Demographics of Target Populations

From the Table of publications listed in Section 7.1.1 addressing the safety of phenylephrine topically applied to the eye, at least 1229 subjects were exposed to phenylephrine of which 630 received phenylephrine 10%.

Since the use of phenylephrine ophthalmic drops 2.5% and 10%, is for examinations and surgical procedures there are no data on long term exposure and safety.

Phenylephrine ophthalmic solution 2.5% results in an acceptable increase of heart rate and blood pressure; due to these increases the higher dose of phenylephrine ophthalmic solution 10% is not recommended in infants less than 1 year old. See Section 7.4.5 of this review.

7.2.2 Explorations for Dose Response

The dose response curve for mydriasis flattens above the 2.5% concentration with little difference between 5% and 10% concentrations (Haddad, 1979). The efficacy difference between the 5% and 10% concentrations is not statistically significant. The optimal dose range appears to be 2.5% to 10%. In general, a subject should receive a dose by instillation, every 3-5 minutes until the desired mydriasis is obtained to a maximum of 3 drops.

7.2.3 Special Animal and/or In Vitro Testing

Phenylephrine hydrochloride is an α -adrenergic receptor sympathetic agonist that has been used for more than 70 years to dilate the pupil in ocular diagnostic, therapeutic and surgical procedures due to its vasoconstrictor and mydriatic action.

Given the extensive use of phenylephrine in humans additional animal / in vitro testing is not required.

7.2.4 Routine Clinical Testing

Additional clinical testing is not required.

7.2.5 Metabolic, Clearance, and Interaction Workup

Metabolic and clearance studies were not performed.

7.2.6 Evaluation for Potential Adverse Events for Similar Drugs in Drug Class

Refer to Section 7.2.5.

7.3 Major Safety Results

7.3.1 Deaths

No deaths were reported due to the use of topical ophthalmic phenylephrine solution.

7.3.2 Nonfatal Serious Adverse Events

Several authors describe the potential for 10% phenylephrine to exacerbate vasoconstrictive conditions and cardiovascular conditions following topical ophthalmic use. Marked elevation of blood pressure, tachycardia, ventricular arrhythmias, myocardial infarction, and subarachnoid hemorrhage are reported as rare reactions following topical ocular instillation. Four cases of worsening of visual loss in subjects with non-arteritic ischemic optic neuropathy after 2.5%

phenylephrine plus 0.5% or 1% tropicamide was used in a dilated fundus exam have been reported.

7.3.3 Dropouts and/or Discontinuations

Not applicable.

7.3.4 Significant Adverse Events

Ophthalmic use of phenylephrine occasionally causes systemic sympathomimetic effects such as palpitation, tachycardia, premature ventricular contractions, occipital headache, pallor or blanching, trembling or tremors, increased perspiration, and hypertension. In one patient, hypertension severe enough to cause subarachnoid hemorrhage followed insertion of a cotton wick saturated with 10% phenylephrine hydrochloride in the lower conjunctival cul-de-sac.

Systemic effects occur only rarely after topical application of solutions containing 2.5% or less of phenylephrine hydrochloride to the conjunctiva but are more likely to occur if the drug is instilled after the corneal epithelium has been damaged (e.g., by trauma or instrumentation) or permeability is increased by tonometry, inflammation, surgery of the eye or adnexa, or topical application of a local anesthetic; when the eye or adnexa are diseased; or when lacrimation is suppressed such as during anesthesia. The risk of severe hypertension is greatest in infants receiving instillations of 10% phenylephrine hydrochloride solutions.

7.3.5 Submission Specific Primary Safety Concerns

Refer to Section 7.3.4.

7.4 Supportive Safety Results

7.4.1 Common Adverse Events

The most common adverse reactions that occur following topical ophthalmic administration of phenylephrine are ocular reactions including eye pain and stinging on instillation, temporary blurred vision, photophobia, and conjunctival sensitization.

7.4.2 Laboratory Findings

There is a potential for 10% phenylephrine to cause an increase in blood pressure particularly systolic blood pressure and to increase or decrease HR. There is evidence that 2.5% is less likely to cause an increase in BP or HR and for this reason is generally preferred in the elderly and the very young.

7.4.3 Vital Signs

Refer to Section 7.4.2.

7.4.4 Electrocardiograms (ECGs)

ECGs findings were not reported.

7.4.5 Special Safety Studies

Special safety studies were performed in neonates in the Sindel 1986 Study and the Borromeo-McGrail 1973 Study. See Section 6.1.4.3 of this review for a more detailed discussion of Sindel 1986.

Sindel Study					
(N=34)					
	Group A	Group B	Group C	Group D	
	Phenylephrine	Phenylephrine	Phenylephrine	Saline only	
	2.5% and	2.5% and	1.0% and		
	1% tropicamide	0.5%	1.0%		
	(N=10)	tropicamide	tropicamide	(N=4)	
		(N=10)	(N=10)		
Age at study	53.9	52.9	52.3	54.0	
(days)					
Birthweight	1022 ± 226	1115 ± 281	1110 ± 317	980 ± 155	
(grams)					
Maxim	Maximum change in blood pressure and heart rate after eye drops instilled				
Blood pressure					
(%)					
Systolic	$+14.9 \pm 9.6*$	$+17.2 \pm 12.5 **$	$+7.1 \pm 10.1$	-0.8 ± 6.9	
Mean	$+17.1 \pm 10.4*$	$+22.8 \pm 17.4$ **	$+7.7 \pm 9.3$ tt	$+3.0 \pm 6.0$	
Diastolic	$+15.9 \pm 7.8*$	$+19.5 \pm 14.2*$	$+5.4 \pm 7.6ttt$	$+0.8 \pm 10.6$	
Heart rate (%)	$+6.0 \pm 6.1*$	$+10.0 \pm 10.6*$	$+4.4 \pm 5.2$	$+2.1 \pm 2.0$	
*					

*p < 0.02 vs. baseline

**p < 0.01 vs. baseline tt A vs. C p=0.04, B vs C p=0.02

ttt A vs. C p=0.007, B vs. C p=0.01

Reviewer's comments:

Phenylephrine ophthalmic solution 2.5% results in an acceptable increase of heart rate and blood pressure in neonates.

Borromeo-McGrail 1973 Study

Borromeo-McGrail 1973 was a randomized, masked study comparing pupillary dilating capabilities and associated cardiovascular effects of phenylephrine hydrochloride ophthalmic solution 2.5%, 10% and saline in 12 neonates under 1 month of age and weighing from 907 gm to 2,438 gm. Formal pupillary measurements were not made or recorded, the article states,"...all patients who received either 2.5% or 10% phenylephrine had full pupillary dilatation within 25 to 30 minutes. The time of onset and degree of dilatation was not related to the concentration of phenylephrine used."

A separate group of eight low birth weight infants was studied in an open phase with 10% phenylephrine ophthalmic instillation. In this phase, the observer was aware that 10% phenylephrine drops had been instilled.

Borromeo-McGrail Study
Double-blind Phase
N=12

All neonates < 1 month old, weighted 907 - 2,450 grams				
	Phenylephrine 2.5%	Phenylephrine 10%	Normal Saline	
	(N=4)	(N=3)	(N=5)	
Blood pressure (%)				
Systolic	unchanged	Increased 12 – 16 mm	unchanged	
-		Hg (18% to 25%)		
Diastolic	unchanged	Increased 10 – 14 mm	unchanged	
		Hg (22% to 50%)		
Heart rate	unchanged	unchanged	unchanged	
Respiratory rate	unchanged	unchanged	unchanged	

All neonates < 1 month old, weighed 907 - 2,438 grams

Borromeo-McGrail Study

Open label Phase

N=8

All neonates < 1 month old, weighed 907 - 2,438 grams

	Phenylephrine 10%
	(N=8)
Blood pressure (%)	
Systolic	Increased 6 – 22 mm Hg
	(7% to 50%)
Diastolic	Increased 4 – 18 mm Hg
	(13% to 70%)
Heart rate	unchanged
Respiratory rate	unchanged

Reviewer's comments:

Phenylephrine ophthalmic solution 2.5% results in an acceptable increase of heart rate and blood pressure in neonates; phenylephrine ophthalmic solution 10% results in an unacceptable increase of heart rate and blood pressure in neonates.

Caution should be exercised in pediatric patients less than 5 years of age.

7.4.6 Immunogenicity

Not applicable.

7.5 Other Safety Explorations

7.5.1 Dose Dependency for Adverse Events

Since the use of phenylephrine ophthalmic drops 2.5% and 10%, is for examinations and surgical procedures there are no data on long term exposure and safety.

7.5.2 Time Dependency for Adverse Events

Phenylephrine is a sympathomimetic and systemic absorption of eye drops is known to occur via the nasal mucosa, cornea, and conjunctiva. Within minutes of application ocular reactions including eye pain and stinging on instillation, temporary blurred vision, photophobia, and conjunctival sensitization may occur.

7.5.3 Drug-Demographic Interactions

The risk of severe hypertension is greatest in infants less than 1 year old receiving instillations of 10% phenylephrine hydrochloride solutions.

Many studies have reviewed the safety of phenylephrine and some authors have excluded subjects with a history of cardiovascular conditions from their studies based on the known and expected risks of using sympathomimetic drugs in such subjects.

7.5.4 Drug-Disease Interactions

In subjects with vasoconstrictive disease of the retina the use of phenylephrine eye drops may make the condition worse leading to additional vision loss.

Four patients (age range 54-82, 1F 3M) diagnosed with non-arteritic ischemic optic neuropathy experienced acute worsening of visual function after instillation of phenylephrine for dilated fundoscopy examination.

Phenylephrine is contraindicated in patients with a history of closed angle glaucoma (unless previously treated with iridectomy) and in patients at risk for narrow angle glaucoma precipitated by mydriatics.

7.5.5 Drug-Drug Interactions

The potential for interaction exists with other drugs administered topically and systemically.

Interaction with topical anticholinergic cycloplegic drugs eg : tropicamide, cyclopentolate hydrochloride, homatropine hydrobromide, or scopolamine hydrobromide and has been shown to be synergistic, resulting in a greater mydriasis. The two drugs are frequently used together for that reason.

The cardiac and pressor effects of phenylephrine are potentiated by prior administration of monoamine oxidase (MAO) inhibitors because the metabolism of phenylephrine is reduced. The potentiation is greater following oral administration of phenylephrine than after parenteral administration of the drug because reduction of the metabolism of phenylephrine in the intestine results in increased absorption of the drug. Topical ocular administration may be regarded as similar to parenteral because of the rapid direct absorption into the blood of the superior vena cava and the heart (McEvoy 2007). Tricyclic antidepressants (e.g., imipramine) or guanethidine may also potentiate the vasopressor effects of phenylephrine. The mydriatic response to phenylephrine may be decreased in patients receiving levodopa (McEvoy 2007).

Rarely, administration of phenylephrine to patients who have received cyclopropane or halogenated hydrocarbon general anesthetics that increase cardiac irritability and seem to sensitize the myocardium to phenylephrine may result in arrhythmias. The manufacturer states that vasopressors should be used only with extreme caution or not at all with these general anesthetics. However, in usual therapeutic doses, phenylephrine is much less likely to produce arrhythmias than is norepinephrine or metaraminol (McEvoy 2007).

7.6 Additional Safety Explorations

7.6.1 Human Carcinogenicity

Human carnicogenicity studies were not performed. There was no evidence of carcinogenicity of phenylephrine hydrochloride in male or female rats given 620 or 1,250 ppm in feed or in male or female mice given 1,250 or 2,500 ppm in feed.

7.6.2 Human Reproduction and Pregnancy Data

It is not known whether phenylephrine can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Phenylephrine ophthalmic solution, 2.5% and 10% should be given to a pregnant woman only if clearly needed.

7.6.3 Pediatrics and Effect on Growth

Phenylephrine ophthalmic solution 10% is contraindicated in pediatric patients less than 1 year of age.

7.6.4 Overdose, Drug Abuse Potential, Withdrawal and Rebound

Rebound miosis has been reported in elderly patients one day after receiving phenylephrine ophthalmic solution, and re instillation of the drug produced a lesser mydriatic effect. This may be of clinical importance in dilating the pupils of older subjects prior to retinal detachment or cataract surgery.

Topical overdosing is unlikely since the excess spills onto the face. However, repeated instillation may be dangerous particularly in the elderly, the very young, those with cardiovascular disease and long standing diabetics.

7.7 Additional Submissions

A 120 Day Safety Update was submitted on February 28,2013.

There is no new safety information that would alter the safety conclusions of the original NDA submission.

8 Postmarketing Experience

This is a Type 7 NDA for a drug already marketed without an approved NDA. These solutions have been manufactured by the drug product manufacturer, (b) (4)

A market review of phenylephrine sales in the US in 2010 showed that approximately (b) (4) mL of eye drops were purchased. Per the applicant, this volume equates to approximately (b) (4) patient exposures annually.

In a FDA Adverse Event Reporting System (FAERS) Standard Case Series Summary Report run December 14, 2012, for "Phenylephrine ophthalmic," the following events were identified:

Preferred Term	Count Of Events	Percent Of Total Cases
TOXIC ANTERIOR SEGMENT SYNDROME	20	15.38%
INFLAMMATION	16	12.31%
EYE DISORDER	15	11.54%
IRIDOCYCLITIS	14	10.77%
BRADYCARDIA	8	6.15%
DRUG EFFECT PROLONGED	7	5.38%
APNOEA	6	4.62%
CYANOSIS	6	4.62%
BLINDNESS	5	3.85%
CORNEAL ABRASION	5	3.85%
EYE PAIN	5	3.85%
MYDRIASIS	5	3.85%
VISUAL IMPAIRMENT	5	3.85%
DIZZINESS	4	3.08%
ENDOPHTHALMITIS	4	3.08%
HYPERTENSION	4	3.08%
HYPOTENSION	4	3.08%
MALAISE	4	3.08%
NECROTISING COLITIS	4	3.08%
VISION BLURRED	4	3.08%
CARDIAC ARREST	3	2.31%
CONJUNCTIVITIS	3	2.31%
DRUG INEFFECTIVE	3	2.31%

Reviewer's comments:

Only a portion of the search is presented here. Many of the counted events are unrelated to the sole use of phenylephrine hydrochloride ophthalmic solution; they appear to be associated with ocular conditions for which topical phenylephrine was used diagnostically or therapeutically to dilate the pupil, e.g. toxic anterior segment syndrome, inflammation, iridocyclitis, etc.

9 Appendices

9.1 Literature Review/References

This review is based on the literature submitted.

EFFICACY

Gambill HD, Ogle KN, Kearns TP. Mydriatic Effect of Four Drugs Determined with Pupillogrpah. Arch Ophthal Vol 77, June 1967, 740-746.

Haddad NJ, Moyer NJ, Riley FC. Mydriatic Effect of Phenylephrine Hydrochloride. Am J Ophthalmol. Nov 1970: 70 (5);729-733.

Chawdhary S, Angra SK, Zutshi R, Sachev S. Mydriasis – use of Phenylephrine (A dose-response concept). Ind J Ophthalmol. July 1984, 34: 213-216.

Yospaiboon P, Luanratanakorn P, Noppawinyoowong C. Randomized Double-Blind Study of Phenylephrine 2.5% vs 10% on Pupillary Dilation. J Med Assoc Thai, 2004; Vol 87:11: 1380-1384.

Sindel BD, Baker MD, Maisels MJ, Weinstein J. A Comparison of the Pupillary and Cardiovascular Effects of Various Mydriatic Agents in Preterm Infants. J Ped Optha and Strabismus. 23(6); 273-6 Nov 1986.

Filho AD, Frasson M, Merula RV, Morais PR, Cronenberger S. Cardiovascular and mydriatic effects of topical phenylephrine 2.5% and 10.0% in healthy volunteers. Arq Bras Oftalmol 2007; 70 (6):961-6.

Ozturk F, Kurt E, Inan UU, Ilker SS. The efficacy of 2.5% pheynylephrine and flurbiprofen combined in inducing and maintaining papillary dilatation during cataract surgery. European J of Ophthal 10; 2:144-148 2000.

Tanner V, Caswell G. A Comparative Study of the Efficacy of 2.5% Phenylephrine and 10% Phenylephrine in Pre-Operative Mydriasis for Routine Cataract Surgery. EYE 1996 10; 95-98.

Eyeson-Annan, Hirst Battistuttat, Green Ophthalmology 1998; 105 (4): 726-32.

Paggiarino DA, Brancata LJ, Newton RE. The Effects of Pupil Size and Accomodation of Sympathetic and Parasympatholytic Agents. Ann Ophthalmol, 1993;25:244-253.

Neuhaus RW, Helper RS. Mydriatic Effect of Phenylephrine 10% (aq) vs Phenylephrine 2.5% (aq). Annals of Ophthalmol Oct 1980: 1159-1160.

SAFETY

Allinson RW, Gerber DS, Bieber S, Hodes BL. Reversal of Mydriasis by Dapiprazole. Ann Ophtalmol 1990: 22; 131-138.

Brown MM, Brown GC, Spaeth GL. Lack of Side Effects From Topically Administered 10% Phenylephrine Eyedrops. Arch Ophthalmol .1980 ,98; 487.

Samantary S, Thomas A: Indian J Ophthalmol 23:16-17, 1975.

Chawdhary S, Angra SK, Zutshi R, Sachev S. Mydriasis – use of Phenylephrine (A dose-response concept). Ind J Ophthalmol. July 1984, 34: 213-216.

Chin KW, Law NM, Chin MK. Phenylephrine Eye Drops in Ophthalmic Surgery – A Clinical Study on Cardiovascular Effects. Med J Malaysia Vol 49.Jun 1994.

Filho AD, Frasson M, Merula RV, Morais PR, Cronenberger S. Cardiovascular and mydriatic effects of topical phenylephrine 2.5% and 10.0% in healthy volunteers. Arq Bras Oftalmol 2007; 70 (6):961-6.

Malhotra, R, Banerjee G, Brampton W, Price NC. Comparison of the cardiovascular effects of 2.5% phenylephrine and 10% phenylephrine during ophthalmic surgery. Eye 1998,12,973-975.

Symons RCA, Walland MJ, Kaufman DV. Letter to the Editor. EYE 1997 11; 947-950.

Yospaiboon P, Luanratanakorn P, Noppawinyoowong C. Randomized Double-Blind Study of Phenylephrine 2.5% vs 10% on Pupillary Dilation. J Med Assoc Thai, 2004; Vol 87:11: 1380- 1384.

Lansche RK. Systemic Reactions to Topical Epinephrine and Phenylephrine. Am J Ophth 1966 61: 95.

Fraunfelder FT, Scafidi AF:. Am J Ophthalmol 85:447, 1978.

Solosko D, Smith RB. Hypertension Following 10 Per Cent Phenylephrine Ophthalmic. Anaesthesiology 1972; 36: 187-9.

Wilensky JT, Woodward HJ. Acute Systemic Hypertension After Conjunctival Instillation of Phenylephrine Hydrochloride. Am J Ophthalmol 1973; 76:156-7

McReynolds WU, Havener WH, Henderson JW. Hazards of the Use of Sympathomimetic Drugs in Ophthalmology. Arch Ophthalmol 1956;56:176-9

Heath P. Neosynephrine: Some Uses and Effects in Ophthalmology. Arch Ophth. 16:839 Nov 1936.

Biggs RD, Alpern M, Bennett DR. The Effect of Sympathomimetic Drugs Upon the Amplitude of Accommodation. AJO 1959 :48 (1 part 2) p169-72.

Becker B, Gage T, Kolker AE, Gay AJ. The Effect of Phenylephrine Hydrochloride on the Miotic-Treated Eye. Am J Ophthalmol;1959; 48: 313-21.

Borromeo-McGrail V, Bordiuk JM, Keitel H. Systemic Hypertension Following Ocular Administration of 10% Phenylephrine in the Neonate. Pediatrics 1973; 53: 1032-6.

Barbee RF, Smith WO. A Comparative Study of Mydriatic and Cycloplegic Agents In Human Subjects Without Eye Disease. Am. J. Ophthalmology 1957 Nov: 44 (5 part 1) 617-22.

Martha Meyer S, Fraunfelder FT. Phenylephrine Hydrochloride. Ophthalmology 1980; 87:1177-1180.

Pless M, Friberg TR, Semin Ophthalmol.2003 Dec;18 (4) :218-21.

Alpay A, Ermis B, Ugurbas SC, Battal F, Sagdik HM. The local vasoconstriction of infant's skin following instillation of mydriatic eye drops. Eur J Clin Pharmacol. 2010 Nov;66(11):1161-4. Epub 2010 Sep 11.

Lee PF. The Influence of Epinephrine and Phenylephrine on Intraocular Pressure. AMA Archives of Ophthalmology Vol 60: Nov 1958. 863-7.

Sindel BD, Baker MD, Maisels MJ, Weinstein J. A Comparison of the Pupillary and Cardiovascular Effects of Various Mydriatic Agents in Preterm Infants. J Ped Optha and Strabismus. 23(6); 273-6 Nov 1986.

Vaughan RW. Ventricular Arrhythmias After Topical Vasocontrictors. Anesth Analg 1973; 52:161-5.

9.2 Advisory Committee Meeting

No Advisory Committee Meeting was held. There were no new issues raised in the review of the application which were thought to benefit from an Advisory Committee Meeting.

9.3 Labeling Recommendations

Following is the draft labeling submitted by the applicant on 10/21/11 (in the "original" NDA submission which received a REFUSAL TO FILE letter).

Revised carton and container labeling and revised package insert, consistent with the revised, track changes versions noted here, should be submitted to the NDA.

Reviewer's Comments:

1) To avoid selection error, revise the color scheme of the labeling (i.e. carton and container labeling) for one of the product strengths from (b) (4) to another color scheme so that they are well differentiated from each another.

2) Change the font color of the proprietary name on the carton and container to a color that provides better contrast against a white background.

3) Ensure that the established name is at least half the size of the proprietary name. Ensure the established name has prominence commensurate with the proprietary name taking into account all pertinent factors including typography, layout, contrast and other printing features per 21 CFR 201.10(g)(2). Remove the blue outline around the letters of the proprietary name unless you also utilize the blue outline on the established name.

4) The strength statement should directly follow after the established name on the principal display panel of the carton and container labels. For example: (b) (4) *(phenylephrine ophthalmic solution)* 2.5%.

5) Revise the net quantity statement to include a space between the number and the unit of measure. For example: 5mL should read 5 (space) mL.

6) Delete or relocate the word (b) (4) that appears directly below the strength statement to a location away from the strength statement.

7) The statement on the container labeling, "Do not use if imprinted seal on cap is torn, broken or missing," is printed in a ^{(b) (4)} font color against a white background. Change the font color to a color that provides better contrast against a white background, such as black.

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

MARTIN P NEVITT 03/05/2013

WILLIAM M BOYD 03/05/2013